verapamil has been researched along with Disease Models, Animal in 274 studies
Verapamil: A calcium channel blocker that is a class IV anti-arrhythmia agent.
verapamil : A racemate comprising equimolar amounts of dexverapamil and (S)-verapamil. An L-type calcium channel blocker of the phenylalkylamine class, it is used (particularly as the hydrochloride salt) in the treatment of hypertension, angina pectoris and cardiac arrhythmia, and as a preventive medication for migraine.
2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile : A tertiary amino compound that is 3,4-dimethoxyphenylethylamine in which the hydrogens attached to the nitrogen are replaced by a methyl group and a 4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl group.
Disease Models, Animal: Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The objective of this study was to investigate the exact therapeutic effects of Verapamil on lipopolysaccharide (LPS)-induced acute lung injury (ALI) and the molecular mechanism involved, through using LPS-induced animal models as well as LPS-stimulated mouse primary peritoneal macrophages models." | 7.91 | The therapeutic effect of verapamil in lipopolysaccharide-induced acute lung injury. ( Han, L; Li, S; Liu, Y; Song, Z; Yuan, L; Zhang, C, 2019) |
| "The efficacy of pathways inhibition and the combined effect of Everolimus (mTOR inhibitor) and Verapamil (CYP3A inhibitor) in ovarian hyperstimulation syndrome (OHSS) need to be tested." | 7.83 | The combination of Everolimus with Verapamil reduces ovarian weight and vascular permeability on ovarian hyperstimulation syndrome: a preclinical experimental randomized controlled study. ( Dalkalitsis, A; Georgiou, I; Kitsou, C; Kosmas, I; Lazaros, L; Mynbaev, O; Prapas, I; Prapas, N; Tinelli, A; Tzallas, C, 2016) |
| " Pentylenetetrazole (PTZ)-kindled and spontaneous model of epilepsy (EL) mice were used as models of chemically induced and spontaneous epilepsy, respectively." | 7.80 | Pharmacoproteomics-based reconstruction of in vivo P-glycoprotein function at blood-brain barrier and brain distribution of substrate verapamil in pentylenetetrazole-kindled epilepsy, spontaneous epilepsy, and phenytoin treatment models. ( Ohtsuki, S; Terasaki, T; Uchida, Y, 2014) |
| " The aim of this study was to compare the suitability of the radiolabelled Pgp inhibitors [(11)C]tariquidar and [(11)C]elacridar with the Pgp substrate radiotracer (R)-[(11)C]verapamil for discriminating tumours expressing low and high levels of Pgp using small-animal PET imaging in a murine breast cancer model." | 7.78 | A comparative small-animal PET evaluation of [11C]tariquidar, [11C]elacridar and (R)-[11C]verapamil for detection of P-glycoprotein-expressing murine breast cancer. ( Bankstahl, JP; Bankstahl, M; Erker, T; Kuntner, C; Langer, O; Löscher, W; Mairinger, S; Müller, M; Sauberer, M; Stanek, J; Strommer, S; Wacheck, V; Wanek, T, 2012) |
| "Verapamil is a useful drug with therapeutic targeting on GCH and a potential way to limit mucous production and improve bronchial inflammation." | 7.78 | Effect of verapamil on bronchial goblet cells of asthma: an experimental study on sensitized animals. ( Ghafarzadegan, K; Hadi, R; Khakzad, MR; Meshkat, M; Mirsadraee, M; Mohammadpour, A; Saghari, M, 2012) |
| "Hydrogen sulfide (H(2) S), generated by enzymes such as cystathionine-γ-lyase (CSE) from L-cysteine, facilitates pain signals by activating the Ca(v) 3." | 7.78 | Involvement of the endogenous hydrogen sulfide/Ca(v) 3.2 T-type Ca2+ channel pathway in cystitis-related bladder pain in mice. ( Hayashi, Y; Kawabata, A; Kubo, L; Matsunami, M; Miki, T; Nishikawa, H; Nishiura, K; Okawa, Y; Ozaki, T; Sekiguchi, F; Tsujiuchi, T, 2012) |
| "The present study was focused to characterize the effects of intrahippocampal application of R-verapamil, a P-glycoprotein blocker, and High Frequency Electrical Stimulation (HFS) at 130 Hz, on seizure susceptibility and extracellular concentrations of glutamate and γ-aminobutyric acid (GABA) in hippocampus of kindled rats with drug-resistant seizures." | 7.77 | Effects of high frequency electrical stimulation and R-verapamil on seizure susceptibility and glutamate and GABA release in a model of phenytoin-resistant seizures. ( Luna-Munguia, H; Orozco-Suarez, S; Rocha, L, 2011) |
| "Aim of this study was to investigate antiarrhythmic and toxic effects of verapamil in mice and rats with thyrotoxicosis and hypothyroidism." | 7.74 | [Characteristics of pharmacological and toxic effects of verapamil during cardiac arrhythmia in thyrotoxic and hypothyroid rats]. ( Afanas'eva, EIu; Arzamastsev, EV; Sokhanenkov, MIu; Sokhanenkova, AE, 2008) |
| "To assess the effect of levosimendan on cardiac output (CO), blood pressure (BP), and heart rate (HR) in a rodent model of severe verapamil poisoning." | 7.74 | Treatment of experimental verapamil poisoning with levosimendan utilizing a rodent model of drug toxicity. ( Graudins, A; Najafi, J; Rur-SC, MP, 2008) |
| "The aim of this study was to investigate the pharmacokinetic changes of verapamil and its major metabolite, norverapamil, after oral administration of verapamil (10 mg/kg) in rabbits with slight, moderate and severe hepatic failure induced by carbon tetrachloride." | 7.73 | Pharmacokinetics of verapamil and its major metabolite, norverapamil from oral administration of verapamil in rabbits with hepatic failure induced by carbon tetrachloride. ( Burm, JP; Choi, JS, 2005) |
| " Combination therapy of valsartan with either amlodipine or verapamil was equally effective in reducing blood pressure to valsartan monotherapy (valsartan + amlodipine 129 +/- 4 valsartan + verapamil 133 +/- 6 mmHg;) but was not as effective at reducing albuminuria." | 7.72 | Disparate effects of angiotensin II antagonists and calcium channel blockers on albuminuria in experimental diabetes and hypertension: potential role of nephrin. ( Allen, TJ; Cao, Z; Cooper, ME; Davis, BJ; de Gasparo, M; Kawachi, H, 2003) |
| " The purpose of this study was to investigate the effects of verapamil and a tocopherol on reperfusion injury in the canine small bowel autotransplantation model." | 7.72 | The effects of alpha - tocopherol and verapamil on mucosal functions after gut ischemia / reperfusion. ( Kilinç, K; Ozdemir, A; Ozenç, A; Yağmurdur, MC, 2003) |
| "To study the influence of the calcium channel blocker verapamil on the development of glaucoma in the adrenalin-induced experimental model of glaucoma." | 7.72 | The influence of the calcium channel blocker verapamil on experimental glaucoma. ( Kashintseva, LT; Kopp, OP; Krizhanovsky, GN; Lipovetskaya, EM; Mikheytseva, IN, 2004) |
| "In an animal model of verapamil-induced shock, endogenous AVP levels increased nearly 40-fold compared with baseline levels." | 7.72 | Use of vasopressin in a canine model of severe verapamil poisoning: a preliminary descriptive study. ( Bond, GR; Johnson, SB; Sztajnkrycer, MD; Weaver, AL, 2004) |
| "We have shown previously that the combination of a long-acting, non-sulfhydryl-containing angiotensin-converting enzyme (ACE) inhibitor (trandolapril) and the Ca2+ channel blocker verapamil improve insulin-stimulated glucose transport in skeletal muscle of the obese Zucker rat, a model of insulin resistance, hyperinsulinemia, and dyslipidemia." | 7.70 | Interactions of captopril and verapamil on glucose tolerance and insulin action in an animal model of insulin resistance. ( Dal Ponte, DB; Fogt, DL; Henriksen, EJ; Jacob, S, 1998) |
| "This study was designed to investigate whether two L-type calcium antagonists, verapamil and nicardipine reduce the myocardial necrosis (infarct size) following ischemia and reperfusion." | 7.70 | [Comparison of effects of verapamil and those of nicardipine on myocardial ischemia and reperfusion injury: a study in an in situ rabbit model]. ( Furuya, M; Yoshida, K, 1999) |
| "Antiarrhythmic effects of bisaramil were examined by using new in vivo triggered arrhythmia models, and they were compared with those of other antiarrhythmic drugs." | 7.69 | Antiarrhythmic effects of bisaramil on triggered arrhythmias produced by intracoronary injection of digitalis and adrenaline in the dog. ( Haruno, A; Hashimoto, K, 1995) |
| "The influence of (+/-)-verapamil and hydralazine on stress- and various chemically-induced gastric ulcers in rats together with their influence on various biochemical parameters which affect the development of the induced ulcers was examined." | 7.69 | Effect of (+/-)-verapamil and hydralazine on stress- and chemically-induced gastric ulcers in rats. ( al-Bekairi, AM; al-Rajhi, AM; Tariq, M, 1994) |
| "The mechanisms of digoxin-induced ventricular arrhythmias were studied in vivo using a novel experimental model." | 7.69 | Digoxin-induced ventricular arrhythmias in the guinea pig heart in vivo: evidence for a role of endogenous catecholamines in the genesis of delayed afterdepolarizations and triggered activity. ( Hurt, CM; Pelleg, A; Xu, J, 1995) |
| "To compare the direct effects of verapamil and diltiazem on the ventricular rate during atrial flutter, we developed an atrial flutter model in guinea pig isolated hearts." | 7.69 | Effects of verapamil and diltiazem on the ventricular rate during simulated atrial flutter in isolated guinea pig hearts. ( Belardinelli, L; Decrinis, M; Domanovits, H; Kasper, K; Stark, G; Stark, U; Sterz, F; Tritthart, HA, 1996) |
| "In our study we have tried to compare the prophylactic effects of superoxide dismutase (SOD), SOD+catalase (CAT), desferrioxamine, verapamil and disulfiram, which are all free oxygen radical (FOR) scavengers, in an animal model of experimental acetic acid colitis." | 7.69 | The prophylactic effects of superoxide dismutase, catalase, desferrioxamine, verapamil and disulfiram in experimental colitis. ( Cokneşelí, B; Köksoy, FN; Köse, H; Soybír, GR; Yalçin, O, 1997) |
| " Common factors were hyperkalemia and verapamil therapy." | 7.68 | Effect of hyperkalemia on experimental myocardial depression by verapamil. ( Jolly, SR; Keaton, N; Movahed, A; Reeves, WC; Rose, GC, 1991) |
| " In the present study, the effects of two calcium blockers, verapamil and nifedipine, were compared in several rodent thrombosis models." | 7.67 | Comparison of verapamil and nifedipine in thrombosis models. ( Forman, G; Myers, AK; Penhos, J; Ramwell, P; Torres Duarte, AP, 1986) |
| "The ability of the calcium entry blocker verapamil to ameliorate the effects of renal ischemia was studied in ten sheep." | 7.67 | Effect of the calcium entry blocker verapamil on renal ischemia. ( Barker, GR; Briggs, BA; Gingrich, GA; Jacobsen, WK; Martin, RD; Melashenko, RA; Stewart, SC; Woolley, JL, 1988) |
| "Heavy male Sprague-Dawley rats die of ventricular fibrillation within 2 to 3 h after isoproterenol administration." | 7.67 | Effects of antiarrhythmic agents on isoproterenol-induced ventricular fibrillation in heavy rats: a possible model of sudden cardiac death. ( Balazs, T; Ehrreich, SJ; el-Hage, AN; Johnson, GL, 1986) |
| "Williams-Beuren syndrome (WBS) is a rare disorder caused by a recurrent microdeletion with hallmarks of cardiovascular manifestations, mainly supra-valvular aortic stenosis (SVAS)." | 5.91 | The Combined Treatment of Curcumin with Verapamil Ameliorates the Cardiovascular Pathology in a Williams-Beuren Syndrome Mouse Model. ( Abdalla, N; Campuzano, V; Egea, G; Ortiz-Romero, P; Pérez-Jurado, LA; Rodriguez-Rovira, I, 2023) |
| "Acute lung injury (ALI) and acute respiratory distress syndrome (ARDS), severe form of ALI, are characterized by overwhelming of lung inflammation, and no treatment is currently available to treat ALI/ARDS." | 5.72 | Verapamil attenuates oxidative stress and inflammatory responses in cigarette smoke (CS)-induced murine models of acute lung injury and CSE-stimulated RAW 264.7 macrophages via inhibiting the NF-κB pathway. ( Aldahish, A; Alqahtani, AM; Alqahtani, T; Fatima, M; Hussain, L; Hussain, M; Jamil, Q; Khan, KU; Mukhtar, I; Saadullah, M; Shaukat, S; Syed, SK; Wu, X; Zeng, LH, 2022) |
| "Hyperoxaluria was induced by continuous administration of ethylene glycol (0." | 5.38 | Hyperoxaluria-induced tubular ischemia: the effects of verapamil and vitamin E on apoptotic changes with an emphasis on renal papilla in rat model. ( Aydin, M; Ekici, ID; Miroglu, C; Sarıca, K; Tanriverdi, O; Telci, D, 2012) |
| "The objective of this study was to evaluate the suitability of the early phase of adjuvant arthritis (pre-AA) as a model of inflammation for pharmacokinetic studies." | 5.33 | Effect of early phase adjuvant arthritis on hepatic P450 enzymes and pharmacokinetics of verapamil: an alternative approach to the use of an animal model of inflammation for pharmacokinetic studies. ( Jamali, F; Ling, S, 2005) |
| "Myocardial infarction is usually induced in small animals by means of invasive procedures: the aim of this study was to cause heart necrosis lesions by non-invasive means." | 5.32 | Myocardial infarction non-invasively induced in rabbits by administering isoproterenol and vasopressin: protective effects exerted by verapamil. ( Bertolini, B; Bonacina, E; Brenna, S; Pinelli, A; Tomasoni, L; Trivulzio, S; Vignati, S, 2004) |
| "Verapamil was administered at a loading dose of 0." | 5.31 | Profibrillatory effects of verapamil but not of digoxin in the goat model of atrial fibrillation. ( Allessie, MA; Duytschaever, MF; Garratt, CJ, 2000) |
| "In previous work, we have shown that the chronic administration of verapamil, a calcium channel blocker, ameliorated the mortality, pathology, and biochemical alterations associated with acute murine Chagas' disease." | 5.28 | Effect of verapamil on the development of chronic experimental Chagas' disease. ( Bilezikian, JP; Factor, SM; Morris, SA; Tanowitz, HB; Weiss, LM; Wittner, M, 1989) |
| "Pretreatment with verapamil reduced the size of these subendocardial infarcts from 34 +/- 8 to 8 +/- 3% of the ischemic circumflex vascular bed at risk (identified by postmortem perfusion of the previously occluded and unoccluded arteries with different dyes)." | 5.27 | Verapamil in two reperfusion models of myocardial infarction. Temporary protection of severely ischemic myocardium without limitation of ultimate infarct size. ( Jennings, RB; Reimer, KA, 1984) |
| " Nicardipine given by three different dosing schedules to baboons markedly limited myocardial infarction over a 6 h period of LAD occlusion." | 5.27 | Nicardipine in models of myocardial infarction. ( Alps, BJ; Calder, C; Wilson, A, 1985) |
| "Benzodiazepine withdrawal, spontaneous or precipitated by the receptor antagonist, flumazenil, produces anxiety that can be measured in animal models." | 4.78 | The benzodiazepines: anxiolytic and withdrawal effects. ( Little, HJ, 1991) |
| " The Ito agonist NS5806, sodium channel blocker ajmaline, calcium channel blocker verapamil or hypothermia (32°C) were used to pharmacologically mimic the genetic defects and conditions associated with JWS, thus eliciting prominent J waves and provoking VT/VF." | 3.96 | Acacetin suppresses the electrocardiographic and arrhythmic manifestations of the J wave syndromes. ( Ackerman, MJ; Antzelevitch, C; Barajas-Martinez, H; Borbáth, V; Burashnikov, A; Clatot, J; Di Diego, JM; Hu, D; Li, GR; Patocskai, B; Robinson, VM, 2020) |
| "The objective of this study was to investigate the exact therapeutic effects of Verapamil on lipopolysaccharide (LPS)-induced acute lung injury (ALI) and the molecular mechanism involved, through using LPS-induced animal models as well as LPS-stimulated mouse primary peritoneal macrophages models." | 3.91 | The therapeutic effect of verapamil in lipopolysaccharide-induced acute lung injury. ( Han, L; Li, S; Liu, Y; Song, Z; Yuan, L; Zhang, C, 2019) |
| "BackgroundIn the clinical setting, verapamil is contraindicated in neonates and infants, because of the perceived risk of hypotension or bradyarrhythmia." | 3.88 | Postnatal developmental changes in the sensitivity of L-type Ca ( Ding, WG; Hoshino, S; Maruo, Y; Matsuura, H; Nakagawa, M; Omatsu-Kanbe, M; Sagawa, H; Yoshioka, K, 2018) |
| "The efficacy of pathways inhibition and the combined effect of Everolimus (mTOR inhibitor) and Verapamil (CYP3A inhibitor) in ovarian hyperstimulation syndrome (OHSS) need to be tested." | 3.83 | The combination of Everolimus with Verapamil reduces ovarian weight and vascular permeability on ovarian hyperstimulation syndrome: a preclinical experimental randomized controlled study. ( Dalkalitsis, A; Georgiou, I; Kitsou, C; Kosmas, I; Lazaros, L; Mynbaev, O; Prapas, I; Prapas, N; Tinelli, A; Tzallas, C, 2016) |
| "The authors showed that verapamil has the ability to improve wound healing by enhancing fibroblast proliferation, collagen bundle synthesis, and revascularization in skin injuries." | 3.83 | Verapamil, a Calcium-Channel Blocker, Improves the Wound Healing Process in Rats with Excisional Full-Thickness Skin Wounds Based on Stereological Parameters. ( Ashkani-Esfahani, S; Fatheazam, R; Hosseinabadi, OK; Kardeh, S; Khoshneviszadeh, M; Mehrvarz, S; Moafpourian, Y; Moezzi, P; Nadimi, E; Noorafshan, A; Rafiee, S, 2016) |
| "Fifty healthy Sprague-Dawley rats were randomly divided into control, severe acute pancreatitis (SAP), Qingyi decoction-treated (QYT), dexamethasone-treated (DEX), and verapamil-treated (VER) groups." | 3.81 | Therapeutic effect of Qingyi decoction in severe acute pancreatitis-induced intestinal barrier injury. ( Chen, HL; Liu, GL; Owusu, L; Wang, GY; Wang, YX; Xu, CM; Zhang, GX; Zhang, JW, 2015) |
| " Thirty mice that developed seizures were randomly divided into three groups and administered PHT as well as the following treatments: saline (negative control); verapamil (20 mg/kg, positive control); and G." | 3.81 | Reversal of P-glycoprotein overexpression by Ginkgo biloba extract in the brains of pentylenetetrazole-kindled and phenytoin-treated mice. ( Chen, SL; Fan, Q; Ma, H; Zhang, C, 2015) |
| " Pentylenetetrazole (PTZ)-kindled and spontaneous model of epilepsy (EL) mice were used as models of chemically induced and spontaneous epilepsy, respectively." | 3.80 | Pharmacoproteomics-based reconstruction of in vivo P-glycoprotein function at blood-brain barrier and brain distribution of substrate verapamil in pentylenetetrazole-kindled epilepsy, spontaneous epilepsy, and phenytoin treatment models. ( Ohtsuki, S; Terasaki, T; Uchida, Y, 2014) |
| " In this study, taking advantage of the transparency of larval zebrafish, Danio rerio, we assessed cardiovascular toxicity of seven known human cardiotoxic drugs (aspirin, clomipramine hydrochloride, cyclophosphamide, nimodipine, quinidine, terfenadine and verapamil hydrochloride) and two non-cardiovascular toxicity drugs (gentamicin sulphate and tetracycline hydrochloride) in zebrafish using six specific phenotypic endpoints: heart rate, heart rhythm, pericardial edema, circulation, hemorrhage and thrombosis." | 3.80 | Human cardiotoxic drugs delivered by soaking and microinjection induce cardiovascular toxicity in zebrafish. ( Dong, QX; Gao, JM; He, JH; Huang, CJ; Li, CQ; Xu, YQ; Xuan, YX; Yu, HP; Zhu, JJ, 2014) |
| " The aim of this study was to compare the suitability of the radiolabelled Pgp inhibitors [(11)C]tariquidar and [(11)C]elacridar with the Pgp substrate radiotracer (R)-[(11)C]verapamil for discriminating tumours expressing low and high levels of Pgp using small-animal PET imaging in a murine breast cancer model." | 3.78 | A comparative small-animal PET evaluation of [11C]tariquidar, [11C]elacridar and (R)-[11C]verapamil for detection of P-glycoprotein-expressing murine breast cancer. ( Bankstahl, JP; Bankstahl, M; Erker, T; Kuntner, C; Langer, O; Löscher, W; Mairinger, S; Müller, M; Sauberer, M; Stanek, J; Strommer, S; Wacheck, V; Wanek, T, 2012) |
| "Verapamil is a useful drug with therapeutic targeting on GCH and a potential way to limit mucous production and improve bronchial inflammation." | 3.78 | Effect of verapamil on bronchial goblet cells of asthma: an experimental study on sensitized animals. ( Ghafarzadegan, K; Hadi, R; Khakzad, MR; Meshkat, M; Mirsadraee, M; Mohammadpour, A; Saghari, M, 2012) |
| "Hydrogen sulfide (H(2) S), generated by enzymes such as cystathionine-γ-lyase (CSE) from L-cysteine, facilitates pain signals by activating the Ca(v) 3." | 3.78 | Involvement of the endogenous hydrogen sulfide/Ca(v) 3.2 T-type Ca2+ channel pathway in cystitis-related bladder pain in mice. ( Hayashi, Y; Kawabata, A; Kubo, L; Matsunami, M; Miki, T; Nishikawa, H; Nishiura, K; Okawa, Y; Ozaki, T; Sekiguchi, F; Tsujiuchi, T, 2012) |
| " The primary endpoint was time to death measured separately as time to asystole and time to apnea." | 3.77 | Effect of cyclodextrin infusion in a rat model of verapamil toxicity. ( Aks, SE; Bryant, SM; Mottram, AR, 2011) |
| "The present study was focused to characterize the effects of intrahippocampal application of R-verapamil, a P-glycoprotein blocker, and High Frequency Electrical Stimulation (HFS) at 130 Hz, on seizure susceptibility and extracellular concentrations of glutamate and γ-aminobutyric acid (GABA) in hippocampus of kindled rats with drug-resistant seizures." | 3.77 | Effects of high frequency electrical stimulation and R-verapamil on seizure susceptibility and glutamate and GABA release in a model of phenytoin-resistant seizures. ( Luna-Munguia, H; Orozco-Suarez, S; Rocha, L, 2011) |
| "Pregnancy increased diazoxide, but not verapamil-induced relaxations." | 3.76 | Role of KATP and L-type Ca2+ channel activities in regulation of ovine uterine vascular contractility: effect of pregnancy and chronic hypoxia. ( Longo, LD; Xiao, D; Zhang, L, 2010) |
| "Aim of this study was to investigate antiarrhythmic and toxic effects of verapamil in mice and rats with thyrotoxicosis and hypothyroidism." | 3.74 | [Characteristics of pharmacological and toxic effects of verapamil during cardiac arrhythmia in thyrotoxic and hypothyroid rats]. ( Afanas'eva, EIu; Arzamastsev, EV; Sokhanenkov, MIu; Sokhanenkova, AE, 2008) |
| "Recently, extensive behavioral research has been conducted on the benztropine (BZT) analogs with the goal of developing successful therapeutics for cocaine abuse." | 3.74 | Transport, metabolism, and in vivo population pharmacokinetics of the chloro benztropine analogs, a class of compounds extensively evaluated in animal models of drug abuse. ( Eddington, ND; Newman, AH; Othman, AA; Syed, SA, 2007) |
| "To assess the effect of levosimendan on cardiac output (CO), blood pressure (BP), and heart rate (HR) in a rodent model of severe verapamil poisoning." | 3.74 | Treatment of experimental verapamil poisoning with levosimendan utilizing a rodent model of drug toxicity. ( Graudins, A; Najafi, J; Rur-SC, MP, 2008) |
| "The aim of this study was to investigate the pharmacokinetic changes of verapamil and its major metabolite, norverapamil, after oral administration of verapamil (10 mg/kg) in rabbits with slight, moderate and severe hepatic failure induced by carbon tetrachloride." | 3.73 | Pharmacokinetics of verapamil and its major metabolite, norverapamil from oral administration of verapamil in rabbits with hepatic failure induced by carbon tetrachloride. ( Burm, JP; Choi, JS, 2005) |
| " We performed a randomized, controlled, blinded trial in a porcine model to study the effects of vasopressin infusion on mean arterial pressure after verapamil poisoning." | 3.73 | Vasopressin treatment of verapamil toxicity in the porcine model. ( Barry, JD; Cantrell, L; Clark, RF; Durkovich, D; Offerman, S; Richardson, W; Tanen, DA; Tong, T; Williams, S, 2005) |
| " Combination therapy of valsartan with either amlodipine or verapamil was equally effective in reducing blood pressure to valsartan monotherapy (valsartan + amlodipine 129 +/- 4 valsartan + verapamil 133 +/- 6 mmHg;) but was not as effective at reducing albuminuria." | 3.72 | Disparate effects of angiotensin II antagonists and calcium channel blockers on albuminuria in experimental diabetes and hypertension: potential role of nephrin. ( Allen, TJ; Cao, Z; Cooper, ME; Davis, BJ; de Gasparo, M; Kawachi, H, 2003) |
| " The purpose of this study was to investigate the effects of verapamil and a tocopherol on reperfusion injury in the canine small bowel autotransplantation model." | 3.72 | The effects of alpha - tocopherol and verapamil on mucosal functions after gut ischemia / reperfusion. ( Kilinç, K; Ozdemir, A; Ozenç, A; Yağmurdur, MC, 2003) |
| "Certain forms of coronary artery disease do not respond to treatment with Ca2+ channel blockers, and a role for endothelin-1 (ET-1) in Ca2+ antagonist-insensitive forms of coronary vasospasm has been suggested; however, the signaling mechanisms involved are unclear." | 3.72 | Endothelin-1 promotes Ca2+ antagonist-insensitive coronary smooth muscle contraction via activation of epsilon-protein kinase C. ( Khalil, RA; McNair, LL; Salamanca, DA, 2004) |
| "To study the influence of the calcium channel blocker verapamil on the development of glaucoma in the adrenalin-induced experimental model of glaucoma." | 3.72 | The influence of the calcium channel blocker verapamil on experimental glaucoma. ( Kashintseva, LT; Kopp, OP; Krizhanovsky, GN; Lipovetskaya, EM; Mikheytseva, IN, 2004) |
| "In an animal model of verapamil-induced shock, endogenous AVP levels increased nearly 40-fold compared with baseline levels." | 3.72 | Use of vasopressin in a canine model of severe verapamil poisoning: a preliminary descriptive study. ( Bond, GR; Johnson, SB; Sztajnkrycer, MD; Weaver, AL, 2004) |
| "In this study two calcium channel blockers (CCB), diltiazem and verapamil, which demonstrate their effects on two different receptor blockage mechanisms, were assessed comparatively in an experimental colitis model regarding the local and systemic effect spectrum." | 3.72 | The comparative effects of calcium channel blockers in an experimental colitis model in rats. ( Akgün, E; Aynaci, M; Ersin, S; Firat, O; Içöz, G; Kiliç, M; Korkut, M; Ozütemiz, O; Zeytunlu, M, 2004) |
| "The potential of the calcium channel antagonist verapamil to cause apoptosis (programmed cell death) is of considerable importance in arterial injury where the loss of smooth muscle cells may contribute to a reduction in intimal hyperplasia development." | 3.71 | Calcium channel antagonist verapamil inhibits neointimal formation and enhances apoptosis in a vascular graft model. ( Angeli, GL; Fletcher, JP; Hawthorne, WJ; Huang, P; Medbury, HJ; Peng, A, 2001) |
| "We have shown previously that the combination of a long-acting, non-sulfhydryl-containing angiotensin-converting enzyme (ACE) inhibitor (trandolapril) and the Ca2+ channel blocker verapamil improve insulin-stimulated glucose transport in skeletal muscle of the obese Zucker rat, a model of insulin resistance, hyperinsulinemia, and dyslipidemia." | 3.70 | Interactions of captopril and verapamil on glucose tolerance and insulin action in an animal model of insulin resistance. ( Dal Ponte, DB; Fogt, DL; Henriksen, EJ; Jacob, S, 1998) |
| "This study was designed to investigate whether two L-type calcium antagonists, verapamil and nicardipine reduce the myocardial necrosis (infarct size) following ischemia and reperfusion." | 3.70 | [Comparison of effects of verapamil and those of nicardipine on myocardial ischemia and reperfusion injury: a study in an in situ rabbit model]. ( Furuya, M; Yoshida, K, 1999) |
| "This study was conducted to determine whether hypertonic sodium bicarbonate would improve the hypotension associated with severe verapamil toxicity compared with volume expansion." | 3.70 | Hypertonic sodium bicarbonate is effective in the acute management of verapamil toxicity in a swine model. ( Curry, SC; Graeme, KA; Reagan, CG; Ruha, AM; Tanen, DA, 2000) |
| "Antiarrhythmic effects of bisaramil were examined by using new in vivo triggered arrhythmia models, and they were compared with those of other antiarrhythmic drugs." | 3.69 | Antiarrhythmic effects of bisaramil on triggered arrhythmias produced by intracoronary injection of digitalis and adrenaline in the dog. ( Haruno, A; Hashimoto, K, 1995) |
| "The influence of (+/-)-verapamil and hydralazine on stress- and various chemically-induced gastric ulcers in rats together with their influence on various biochemical parameters which affect the development of the induced ulcers was examined." | 3.69 | Effect of (+/-)-verapamil and hydralazine on stress- and chemically-induced gastric ulcers in rats. ( al-Bekairi, AM; al-Rajhi, AM; Tariq, M, 1994) |
| "The mechanisms of digoxin-induced ventricular arrhythmias were studied in vivo using a novel experimental model." | 3.69 | Digoxin-induced ventricular arrhythmias in the guinea pig heart in vivo: evidence for a role of endogenous catecholamines in the genesis of delayed afterdepolarizations and triggered activity. ( Hurt, CM; Pelleg, A; Xu, J, 1995) |
| " The atherogenic significance of Ca ions and arterial Ca overload was examined under the influence of nicotine, oxidatively modified low-density lipoproteins, spontaneous hypertension, and an elevated extracellular Ca concentration or vitamin D3." | 3.69 | Experimental vasoprotection by calcium antagonists against calcium-mediated arteriosclerotic alterations. ( Czirfuzs, A; Fleckenstein-Grün, G; Frey, M; Matyas, S; Thimm, F, 1994) |
| "Contrast-enhanced magnetic resonance (MR) imaging was used to detect and quantify the extent of myocardial injury after a brief coronary occlusion and reperfusion in response to verapamil treatment in a rat model of left ventricular hypertrophy (LVH)." | 3.69 | Verapamil reduces the size of reperfused ischemically injured myocardium in hypertrophied rat hearts as assessed by magnetic resonance imaging. ( Derugin, N; Higgins, CB; Lauerma, K; Saeed, M; Wendland, MF; Yu, KK, 1996) |
| "For the evaluation of the hemodynamic interaction between the natural heart and an assist device, a reversible pharmacological model based on the channel blocker Verapamil under hyperkalemia, was developed for deterioration of left ventricular function." | 3.69 | Pharmacologically induced heart failure for the evaluation of circulatory assistance. ( Losert, U; Roschal, K; Schima, H; Schmidt, C; Schwendenwein, I; Wieselthaler, G; Wolner, E, 1996) |
| "To compare the direct effects of verapamil and diltiazem on the ventricular rate during atrial flutter, we developed an atrial flutter model in guinea pig isolated hearts." | 3.69 | Effects of verapamil and diltiazem on the ventricular rate during simulated atrial flutter in isolated guinea pig hearts. ( Belardinelli, L; Decrinis, M; Domanovits, H; Kasper, K; Stark, G; Stark, U; Sterz, F; Tritthart, HA, 1996) |
| "It is well documented that quinine induces reversible hearing loss and tinnitus." | 3.69 | Quinine-induced hearing loss in the guinea pig is not affected by the Ca2+ channel antagonist verapamil. ( Alván, G; Idrizbegovic, E; Jäger, W; Karlsson, KK, 1997) |
| "In our study we have tried to compare the prophylactic effects of superoxide dismutase (SOD), SOD+catalase (CAT), desferrioxamine, verapamil and disulfiram, which are all free oxygen radical (FOR) scavengers, in an animal model of experimental acetic acid colitis." | 3.69 | The prophylactic effects of superoxide dismutase, catalase, desferrioxamine, verapamil and disulfiram in experimental colitis. ( Cokneşelí, B; Köksoy, FN; Köse, H; Soybír, GR; Yalçin, O, 1997) |
| "A study was performed to examine the effects of the calcium-channel blocker levemopamil on neurologic outcome and neuropathology in a clinically relevant model of complete global cerebral ischemia (ventricular fibrillation in cats)." | 3.68 | Effects of levemopamil on neurologic and histologic outcome after cardiac arrest in cats. ( Drummond, JC; Fleischer, JE; Grafe, MR; Nakakimura, K; Scheller, MS; Shapiro, HM; Zornow, MH, 1992) |
| " Common factors were hyperkalemia and verapamil therapy." | 3.68 | Effect of hyperkalemia on experimental myocardial depression by verapamil. ( Jolly, SR; Keaton, N; Movahed, A; Reeves, WC; Rose, GC, 1991) |
| "To provide evidence to support the calcium hypothesis of cerebral ischemia, we examined the effects of extracellular calcium and calcium antagonists (verapamil, flunarizine, nicardipine) on in vitro 'ischemia' using guinea pig hippocampal slices." | 3.68 | Effects of calcium and calcium antagonists against deprivation of glucose and oxygen in guinea pig hippocampal slices. ( Amagasa, M; Ogawa, A; Yoshimoto, T, 1990) |
| " In the present study, the effects of two calcium blockers, verapamil and nifedipine, were compared in several rodent thrombosis models." | 3.67 | Comparison of verapamil and nifedipine in thrombosis models. ( Forman, G; Myers, AK; Penhos, J; Ramwell, P; Torres Duarte, AP, 1986) |
| "The ability of the calcium entry blocker verapamil to ameliorate the effects of renal ischemia was studied in ten sheep." | 3.67 | Effect of the calcium entry blocker verapamil on renal ischemia. ( Barker, GR; Briggs, BA; Gingrich, GA; Jacobsen, WK; Martin, RD; Melashenko, RA; Stewart, SC; Woolley, JL, 1988) |
| " The dihydropyridine agents, CRE-223 and Nifedipine, were highly protective against experimental thrombosis, whereas Verapamil had a weaker and much shorter effect and, on the other hand, Diltiazem had no protective effect over a range of doses." | 3.67 | The antithrombogenic in vivo effects of calcium channel blockers in experimental thrombosis in mice. ( Ortega, MP; Priego, JG; Statkow, PR; Sunkel, C, 1987) |
| "The effect of an antioxidant dibunol and calcium antagonist verapamil on postperfusion release of myoglobin (Mb) and MB-creatine kinase (MB-CK) has been assessed in 30 dogs with experimental coronary occlusive myocardial infarction." | 3.67 | [Effect of dibunol and isoptin on the creatine kinase and myoglobin content of the blood serum in dogs undergoing postischemic coronary reperfusion]. ( Avilova, OA; Berestov, AA; Golikov, AP; Konorev, EA; Polumiskov, VIu, 1987) |
| "Heavy male Sprague-Dawley rats die of ventricular fibrillation within 2 to 3 h after isoproterenol administration." | 3.67 | Effects of antiarrhythmic agents on isoproterenol-induced ventricular fibrillation in heavy rats: a possible model of sudden cardiac death. ( Balazs, T; Ehrreich, SJ; el-Hage, AN; Johnson, GL, 1986) |
| "To evaluate the mechanism of obesity-induced changes in pharmacokinetics and pharmacodynamics of verapamil observed in humans, single-dose and steady-state kinetic/dynamic studies in obese Zucker rats were done." | 3.67 | Pharmacokinetics and dynamics of (+/-)-verapamil in lean and obese Zucker rats. ( Abernethy, DR; Todd, EL, 1986) |
| "Verapamil was found to be an effective inhibitor of isometric tension in in vitro, experimental anaphylaxis in guinea pig trachealis smooth muscle." | 3.66 | Effect of calcium antagonists in experimental asthma. ( Barbero, L; Markowicz, J; Weiss, EB, 1982) |
| " However, in vitro experiments are not satisfactory to predict antiarrhythmic activity "in vivo", because: 1) they are mostly performed in preparations made from the normal myocardium; 2) "in vitro" the autonomic and hormonal effects are absent; 3) some drugs as nitroglycerin or strophanthin do not produce antiarrhythmic electrophysiological changes in "vitro" but under appropriate conditions they may have a clear-cut antiarrhythmic action "in vivo"; 4) arrhythmias mostly arise from the interaction of changes in several fundamental electrophysiological parameters which could be best studied "in vivo"." | 3.66 | [Pharmacologic evaluation of electrical processes in the myocardium]. ( Sekeresh, L, 1982) |
| "Primary liver cancer patients (100) were randomly assigned into two groups." | 2.77 | Basic and clinical research on the therapeutic effect of intervention in primary liver cancer by targeted intra-arterial verapamil infusion. ( Liting, Q; Pingsheng, F; Qiang, H; Qiang, W; Tengyue, Z; Xin, S, 2012) |
| "Mycophenolic acid was detected in all cats." | 2.61 | ( Abrams, G; Adolfsson, E; Agarwal, PK; Akkan, AG; Al Alhareth, NS; Alves, VGL; Armentano, R; Bahroos, E; Baig, M; Baldridge, KK; Barman, S; Bartolucci, C; Basit, A; Bertoli, SV; Bian, L; Bigatti, G; Bobenko, AI; Boix, PP; Bokulic, T; Bolink, HJ; Borowiec, J; Bulski, W; Burciaga, J; Butt, NS; Cai, AL; Campos, AM; Cao, G; Cao, Y; Čapo, I; Caruso, ML; Chao, CT; Cheatum, CM; Chelminski, K; Chen, AJW; Chen, C; Chen, CH; Chen, D; Chen, G; Chen, H; Chen, LH; Chen, R; Chen, RX; Chen, X; Cherdtrakulkiat, R; Chirvony, VS; Cho, JG; Chu, K; Ciurlino, D; Coletta, S; Contaldo, G; Crispi, F; Cui, JF; D'Esposito, M; de Biase, S; Demir, B; Deng, W; Deng, Z; Di Pinto, F; Domenech-Ximenos, B; Dong, G; Drácz, L; Du, XJ; Duan, LJ; Duan, Y; Ekendahl, D; Fan, W; Fang, L; Feng, C; Followill, DS; Foreman, SC; Fortunato, G; Frew, R; Fu, M; Gaál, V; Ganzevoort, W; Gao, DM; Gao, X; Gao, ZW; Garcia-Alvarez, A; Garza, MS; Gauthier, L; Gazzaz, ZJ; Ge, RS; Geng, Y; Genovesi, S; Geoffroy, V; Georg, D; Gigli, GL; Gong, J; Gong, Q; Groeneveld, J; Guerra, V; Guo, Q; Guo, X; Güttinger, R; Guyo, U; Haldar, J; Han, DS; Han, S; Hao, W; Hayman, A; He, D; Heidari, A; Heller, S; Ho, CT; Ho, SL; Hong, SN; Hou, YJ; Hu, D; Hu, X; Hu, ZY; Huang, JW; Huang, KC; Huang, Q; Huang, T; Hwang, JK; Izewska, J; Jablonski, CL; Jameel, T; Jeong, HK; Ji, J; Jia, Z; Jiang, W; Jiang, Y; Kalumpha, M; Kang, JH; Kazantsev, P; Kazemier, BM; Kebede, B; Khan, SA; Kiss, J; Kohen, A; Kolbenheyer, E; Konai, MM; Koniarova, I; Kornblith, E; Krawetz, RJ; Kreouzis, T; Kry, SF; Laepple, T; Lalošević, D; Lan, Y; Lawung, R; Lechner, W; Lee, KH; Lee, YH; Leonard, C; Li, C; Li, CF; Li, CM; Li, F; Li, J; Li, L; Li, S; Li, X; Li, Y; Li, YB; Li, Z; Liang, C; Lin, J; Lin, XH; Ling, M; Link, TM; Liu, HH; Liu, J; Liu, M; Liu, W; Liu, YP; Lou, H; Lu, G; Lu, M; Lun, SM; Ma, Z; Mackensen, A; Majumdar, S; Martineau, C; Martínez-Pastor, JP; McQuaid, JR; Mehrabian, H; Meng, Y; Miao, T; Miljković, D; Mo, J; Mohamed, HSH; Mohtadi, M; Mol, BWJ; Moosavi, L; Mosdósi, B; Nabu, S; Nava, E; Ni, L; Novakovic-Agopian, T; Nyamunda, BC; Nyul, Z; Önal, B; Özen, D; Özyazgan, S; Pajkrt, E; Palazon, F; Park, HW; Patai, Á; Patai, ÁV; Patzke, GR; Payette, G; Pedoia, V; Peelen, MJCS; Pellitteri, G; Peng, J; Perea, RJ; Pérez-Del-Rey, D; Popović, DJ; Popović, JK; Popović, KJ; Posecion, L; Povall, J; Prachayasittikul, S; Prachayasittikul, V; Prat-González, S; Qi, B; Qu, B; Rakshit, S; Ravelli, ACJ; Ren, ZG; Rivera, SM; Salo, P; Samaddar, S; Samper, JLA; Samy El Gendy, NM; Schmitt, N; Sekerbayev, KS; Sepúlveda-Martínez, Á; Sessolo, M; Severi, S; Sha, Y; Shen, FF; Shen, X; Shen, Y; Singh, P; Sinthupoom, N; Siri, S; Sitges, M; Slovak, JE; Solymosi, N; Song, H; Song, J; Song, M; Spingler, B; Stewart, I; Su, BL; Su, JF; Suming, L; Sun, JX; Tantimavanich, S; Tashkandi, JM; Taurbayev, TI; Tedgren, AC; Tenhunen, M; Thwaites, DI; Tibrewala, R; Tomsejm, M; Triana, CA; Vakira, FM; Valdez, M; Valente, M; Valentini, AM; Van de Winckel, A; van der Lee, R; Varga, F; Varga, M; Villarino, NF; Villemur, R; Vinatha, SP; Vincenti, A; Voskamp, BJ; Wang, B; Wang, C; Wang, H; Wang, HT; Wang, J; Wang, M; Wang, N; Wang, NC; Wang, Q; Wang, S; Wang, X; Wang, Y; Wang, Z; Wen, N; Wesolowska, P; Willis, M; Wu, C; Wu, D; Wu, L; Wu, X; Wu, Z; Xia, JM; Xia, X; Xia, Y; Xiao, J; Xiao, Y; Xie, CL; Xie, LM; Xie, S; Xing, Z; Xu, C; Xu, J; Yan, D; Yan, K; Yang, S; Yang, X; Yang, XW; Ye, M; Yin, Z; Yoon, N; Yoon, Y; Yu, H; Yu, K; Yu, ZY; Zhang, B; Zhang, GY; Zhang, H; Zhang, J; Zhang, M; Zhang, Q; Zhang, S; Zhang, W; Zhang, X; Zhang, Y; Zhang, YW; Zhang, Z; Zhao, D; Zhao, F; Zhao, P; Zhao, W; Zhao, Z; Zheng, C; Zhi, D; Zhou, C; Zhou, FY; Zhu, D; Zhu, J; Zhu, Q; Zinyama, NP; Zou, M; Zou, Z, 2019) |
| " In experimental chronic renal failure, the long-term administration of verapamil protects against renal dysfunction and damage, independent of any effect on systemic mean arterial pressure." | 2.38 | Role of calcium channel blockers in protection against experimental renal injury. ( Schrier, RW, 1991) |
| "Pretreatment with verapamil essentially ablated the phenomenon of postischemic stunning: segment shortening was restored to 115 +/- 8% of normal after 3 h of reflow (p less than 0." | 2.37 | Effect of verapamil on postischemic "stunned" myocardium: importance of the timing of treatment. ( Kloner, RA; Przyklenk, K, 1988) |
| "Pretreatment with verapamil reduced the size of these subendocardial infarcts from 34 +/- 8 to 8 +/- 3% of the ischemic circumflex vascular bed (anatomic area at risk)." | 2.37 | Effects of calcium-channel blockers on myocardial preservation during experimental acute myocardial infarction. ( Jennings, RB; Reimer, KA, 1985) |
| "Williams-Beuren syndrome (WBS) is a rare disorder caused by a recurrent microdeletion with hallmarks of cardiovascular manifestations, mainly supra-valvular aortic stenosis (SVAS)." | 1.91 | The Combined Treatment of Curcumin with Verapamil Ameliorates the Cardiovascular Pathology in a Williams-Beuren Syndrome Mouse Model. ( Abdalla, N; Campuzano, V; Egea, G; Ortiz-Romero, P; Pérez-Jurado, LA; Rodriguez-Rovira, I, 2023) |
| "Acute lung injury (ALI) and acute respiratory distress syndrome (ARDS), severe form of ALI, are characterized by overwhelming of lung inflammation, and no treatment is currently available to treat ALI/ARDS." | 1.72 | Verapamil attenuates oxidative stress and inflammatory responses in cigarette smoke (CS)-induced murine models of acute lung injury and CSE-stimulated RAW 264.7 macrophages via inhibiting the NF-κB pathway. ( Aldahish, A; Alqahtani, AM; Alqahtani, T; Fatima, M; Hussain, L; Hussain, M; Jamil, Q; Khan, KU; Mukhtar, I; Saadullah, M; Shaukat, S; Syed, SK; Wu, X; Zeng, LH, 2022) |
| "Oral treatment with verapamil or vehicle was started, 24 h post-intracerebroventricular (ICV) streptozotocin/(STZ), in 12-month-old animals and continued for 3 months." | 1.62 | Verapamil Prevents Development of Cognitive Impairment in an Aged Mouse Model of Sporadic Alzheimer's Disease. ( Ahmed, HA; Ishrat, T; Ismael, S; Mirzahosseini, G, 2021) |
| "In an orthotopic murine model of pancreatic cancer, AES-135 prolongs survival significantly, therefore representing a candidate for further preclinical testing." | 1.51 | Identification and Characterization of AES-135, a Hydroxamic Acid-Based HDAC Inhibitor That Prolongs Survival in an Orthotopic Mouse Model of Pancreatic Cancer. ( Adile, AA; Bakhshinyan, D; Berger-Becvar, A; de Araujo, ED; Deininger, MW; Fishel, ML; Gawel, JM; Geletu, M; Grimard, ML; Gunning, PT; Heaton, WL; Konieczny, SF; Luchman, HA; O'Hare, T; Raouf, YS; Shah, F; Shouksmith, AE; Singh, SK; Venugopal, C; Weiss, S, 2019) |
| "Cancer is the second most common cause of death, and nanomedicine is regarded as one of the strategies that may revolutionize cancer treatments." | 1.51 | Designing nanoparticles with improved tumor penetration: surface properties from the molecular architecture viewpoint. ( Appelhans, D; Feng, S; Hao, P; Peng, B; Yang, D; Zan, X; Zhang, L; Zhang, T, 2019) |
| "The formation of hypertrophic scaring (HSc) is an abnormal wound-healing response." | 1.46 | A Comparison of Gene Expression of Decorin and MMP13 in Hypertrophic Scars Treated With Calcium Channel Blocker, Steroid, and Interferon: A Human-Scar-Carrying Animal Model Study. ( Chuang, SS; Hsiao, YC; Yang, JY; Yang, SY, 2017) |
| "Verapamil overdose is has a comparatively high mortality rate and there is no effective antidote." | 1.43 | Comparison of Effects of Separate and Combined Sugammadex and Lipid Emulsion Administration on Hemodynamic Parameters and Survival in a Rat Model of Verapamil Toxicity. ( Ates, NG; Demir Piroglu, I; Demir, A; Gergerli, R; Guven, S; Karakilic, E; Kose, HC; Piroglu, MD; Tulgar, S, 2016) |
| " The extract caused rightward shift of the Ca(++) dose-response curves, similar to that caused by verapamil, indicating that it produced vasorelaxation by inhibiting extracellular Ca(2+) influx." | 1.43 | Antihypertensive activity of 80% methanol seed extract of Calpurnia aurea (Ait.) Benth. subsp. aurea (Fabaceae) is mediated through calcium antagonism induced vasodilation. ( Engidawork, E; Getiye, Y; Tolessa, T, 2016) |
| "Due to the complex nature of Alzheimer's disease, multi-target-directed ligand approaches are one of the most promising strategies in the search for effective treatments." | 1.42 | Synthesis of new N-benzylpiperidine derivatives as cholinesterase inhibitors with β-amyloid anti-aggregation properties and beneficial effects on memory in vivo. ( Bajda, M; Brus, B; Czerwińska, P; Filipek, B; Gobec, S; Malawska, B; Sałat, K; Więckowska, A; Więckowski, K, 2015) |
| "Bedaquiline is a newly approved drug for the treatment of multidrug-resistant tuberculosis, but there are concerns about its safety in humans." | 1.42 | Verapamil increases the bactericidal activity of bedaquiline against Mycobacterium tuberculosis in a mouse model. ( Bishai, WR; Gupta, S; Tyagi, S, 2015) |
| "Nitrofen-treated lungs exhibited an increased number of proliferating Sox9-positive distal epithelial progenitor cells, which were decreased and normalized by treatment with carbachol." | 1.42 | Defective parasympathetic innervation is associated with airway branching abnormalities in experimental CDH. ( Gittes, GK; Potoka, DA; Rhodes, J; Saxena, D; Zhang, G, 2015) |
| "Arterial hypertension is an important risk factor for cerebrovascular diseases, such as transient ischemic attacks or stroke, and represents a major global health issue." | 1.39 | Multimodal imaging in rats reveals impaired neurovascular coupling in sustained hypertension. ( Buck, A; Calcinaghi, N; Fritschy, JM; Jolivet, R; Keller, AL; Matter, CM; Singh, A; Weber, B; Winnik, S; Wyss, MT, 2013) |
| "Effects of verapamil on arrhythmias induced by Bay K8644 (a calcium channel agonist) were also determined." | 1.39 | Anti-arrhythmic effect of verapamil is accompanied by preservation of cx43 protein in rat heart. ( Chen, M; Pei, JM; Wang, QL; Wu, Q; Zhang, SM; Zhou, P, 2013) |
| "Various potential molecules with putative positive role in stroke pathology have failed to confer neuro-protection in animal models due to their insufficient bioavailability in brain." | 1.39 | Verapamil augments the neuroprotectant action of berberine in rat model of transient global cerebral ischemia. ( Chopra, K; Singh, DP, 2013) |
| "Hyperoxaluria was induced by continuous administration of ethylene glycol (0." | 1.38 | Hyperoxaluria-induced tubular ischemia: the effects of verapamil and vitamin E on apoptotic changes with an emphasis on renal papilla in rat model. ( Aydin, M; Ekici, ID; Miroglu, C; Sarıca, K; Tanriverdi, O; Telci, D, 2012) |
| "At least, part of antiseizure effects of cannabinoid compounds is mediated through calcium (Ca(2+)) channels." | 1.38 | L-type calcium channel mediates anticonvulsant effect of cannabinoids in acute and chronic murine models of seizure. ( Ahmad-Molaei, L; Eslahkar, S; Mazar-Atabaki, A; Motiei-Langroudi, SM; Naderi, N; Ronaghi, A; Shirazi-zand, Z, 2012) |
| "In verapamil-treated mice, no contrast enhancement was observed." | 1.38 | In vivo imaging of human breast cancer mouse model with high level expression of calcium sensing receptor at 3T. ( Baio, G; Carbotti, G; Cilli, M; Emionite, L; Fabbi, M; Ghedin, P; Neumaier, CE; Prato, S; Salvi, S; Tagliafico, A; Truini, M, 2012) |
| "Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a familial arrhythmic syndrome caused by mutations in genes encoding the calcium-regulation proteins cardiac ryanodine receptor (RyR2) or calsequestrin-2 (CASQ2)." | 1.37 | Prevention of ventricular arrhythmia and calcium dysregulation in a catecholaminergic polymorphic ventricular tachycardia mouse model carrying calsequestrin-2 mutation. ( Alcalai, R; Arad, M; Berul, CI; Konno, T; Planer, D; Seidman, CE; Seidman, JG; Wakimoto, H; Wang, L, 2011) |
| "Huntington disease is a neurodegenerative disease with complex pathophysiology." | 1.37 | Attenuation of proinflammatory cytokines and apoptotic process by verapamil and diltiazem against quinolinic acid induced Huntington like alterations in rats. ( Kalonia, H; Kumar, A; Kumar, P, 2011) |
| "Verapamil treatment reduced both cardiac (P < 0." | 1.37 | Interdependence of cardiac iron and calcium in a murine model of iron overload. ( Brewer, C; Otto-Duessel, M; Wood, JC, 2011) |
| "Multiorgan metastasis of drug-resistant 4T1 breast tumors was totally resistant to doxorubicin treatment." | 1.37 | Increased expression of P-glycoprotein is associated with doxorubicin chemoresistance in the metastatic 4T1 breast cancer model. ( Bao, L; Dash, S; Haque, A; Hazari, S; Jackson, K; Jetly, R; Moroz, K, 2011) |
| " Plasma concentrations of verapamil in DM rats, rats fed with HFD, and control (CON) rats were measured after intravenous administration of 1 mg/kg verapamil and corresponding pharmacokinetic parameters were estimated." | 1.37 | Pharmacokinetics of verapamil in diabetic rats induced by combination of high-fat diet and streptozotocin injection. ( Chen, GM; Hu, N; Li, J; Liu, L; Liu, XD; Wang, GJ; Wang, P; Xie, L; Xie, SS, 2011) |
| "Verapamil and reserpine were included to determine their effect on rifampicin and ofloxacin susceptibility." | 1.37 | Rifampicin reduces susceptibility to ofloxacin in rifampicin-resistant Mycobacterium tuberculosis through efflux. ( Gey van Pittius, NC; Grobbelaar, M; Hernandez-Pando, R; Jimenez, A; Leon, R; Louw, GE; McEvoy, CR; Murray, M; van Helden, PD; Victor, TC; Warren, RM, 2011) |
| "To reveal putative seizure-induced changes in blood-brain barrier integrity, we performed gadolinium-enhanced magnetic resonance scans on a 7." | 1.37 | A novel positron emission tomography imaging protocol identifies seizure-induced regional overactivity of P-glycoprotein at the blood-brain barrier. ( Bankstahl, JP; Bankstahl, M; Ding, XQ; Kuntner, C; Langer, O; Löscher, W; Meier, M; Müller, M; Stanek, J; Wanek, T, 2011) |
| "L-carnitine is an essential compound involved in cellular energy production through free fatty acid metabolism." | 1.37 | L-carnitine increases survival in a murine model of severe verapamil toxicity. ( Bania, T; Chu, J; Medlej, K; Perez, E, 2011) |
| "Verapamil response was significantly correlated with cTnI." | 1.36 | Drug-disease interaction: reduced verapamil response in isoproterenol-induced myocardial injury in rats. ( El-Kadi, AO; Hanafy, S; Jamali, F, 2010) |
| " Combination therapy can reduce the dosage of each drug but achieve equal or better efficacy than monotherapy, reducing the side effects of a single drug." | 1.36 | The effect of combined steroid and calcium channel blocker injection on human hypertrophic scars in animal model: a new strategy for the treatment of hypertrophic scars. ( Huang, CY; Yang, JY, 2010) |
| "The ability of CCBs to produce catalepsy in mice was also evaluated in the study." | 1.36 | Anti-psychotic and sedative effect of calcium channel blockers in mice. ( Bakre, TO; Onwuchekwa, C; Umukoro, S, 2010) |
| "Verapamil toxicity was achieved by a constant infusion of 15 mg/kg/hr." | 1.35 | Determining the optimal dose of intravenous fat emulsion for the treatment of severe verapamil toxicity in a rodent model. ( Bania, TC; Chu, J; Medlej, K; Perez, E, 2008) |
| "Diltiazem treatment (10 mg/kg/d) had essentially no effect on WT and V394L GCase protein or activity levels (<1." | 1.35 | In vivo and ex vivo evaluation of L-type calcium channel blockers on acid beta-glucosidase in Gaucher disease mouse models. ( Grabowski, GA; Liou, B; Quinn, B; Ran, H; Sun, Y; Xu, YH, 2009) |
| " In the other two routes of administration via the tail vein and hepatic portal vein, diammonium glycyrrhizinate (15 mg kg(-1)) did not affect any of the pharmacokinetic parameters of aconitine (0." | 1.35 | Effects of diammonium glycyrrhizinate on the pharmacokinetics of aconitine in rats and the potential mechanism. ( Chen, L; Chen, YX; Davey, AK; Liu, XQ; Wang, JP; Yang, J, 2009) |
| "The objective of this study was to evaluate the suitability of the early phase of adjuvant arthritis (pre-AA) as a model of inflammation for pharmacokinetic studies." | 1.33 | Effect of early phase adjuvant arthritis on hepatic P450 enzymes and pharmacokinetics of verapamil: an alternative approach to the use of an animal model of inflammation for pharmacokinetic studies. ( Jamali, F; Ling, S, 2005) |
| "Verapamil is a lipid-soluble calcium channel blocker with significant mortality in overdose." | 1.33 | Intralipid prolongs survival in a rat model of verapamil toxicity. ( Cave, G; Harvey, M; Nicholson, T; Tebbutt, S, 2006) |
| "Septic shock has a high mortality rate due to the hypotension and circulatory disorder that occurs during its pathogenesis." | 1.33 | Effects of verapamil and nifedipine on different parameters in lipopolysaccharide-induced septic shock. ( Erol, K; Kilic, FS; Sirmagul, B; Tunc, O; Yildirim, E, 2006) |
| "Essential hypertension is a common disease caused by a combination of genetic and environmental factors." | 1.32 | Low urinary kallikrein rats: different sensitivity of verapamil on hypertensive response to central acute cadmium administration. ( Anania, V; Palomba, D; Satta, M; Varoni, MV, 2003) |
| "Verapamil is known to suppress shortening of the atrial effective refractory period (AERP) during relatively short-term atrial pacing, although the effect of a long-term stimulation model is unclear." | 1.32 | Verapamil suppresses the inhomogeneity of electrical remodeling in a canine long-term rapid atrial stimulation model. ( Inuo, K; Izumi, T; Kojima, J; Moriguchi, M; Niwano, S; Yoshizawa, N, 2003) |
| "Verapamil treatment eliminated evidence of vasospasm and ameliorated histological and functional evidence of cardiomyopathic progression." | 1.32 | Secondary coronary artery vasospasm promotes cardiomyopathy progression. ( Collins, KA; Earley, JU; Hack, AA; Korcarz, CE; Lang, RM; Lapidos, KA; Lyons, MR; McNally, EM; Wheeler, MT; Zarnegar, S, 2004) |
| "These findings, consistent with a dilated cardiomyopathy, were ameliorated in the early but not in the late treatment group, demonstrating that late treatment with verapamil is ineffective in reversing the development of chagasic cardiomyopathy in chronically infected mice." | 1.32 | Effects of early and late verapamil administration on the development of cardiomyopathy in experimental chronic Trypanosoma cruzi (Brazil strain) infection. ( Chandra, M; De Souza, AP; Factor, SM; Huang, H; Jelicks, LA; Morris, SA; Shirani, J; Shtutin, V; Tanowitz, HB; Weiss, LM; Wittner, M, 2004) |
| "The verapamil rate was changed to 4 mg/kg/hr and continued for the next five hours." | 1.32 | Dose-dependent hemodynamic effect of digoxin therapy in severe verapamil toxicity. ( Almond, G; Bania, TC; Chu, J; Perez, E, 2004) |
| "Quercetin and verapamil treatments reduced the endothelium-independent hyper-reactivity to KCl observed in the aorta of DOCA-salt-hypertensive rats, but only quercetin increased the contractile responses to angiotensin II, improved endothelial dysfunction and restored basal aortic Cu/Zn SOD expression, altered in DOCA-salt-treated rats." | 1.32 | Effects of quercetin treatment on vascular function in deoxycorticosterone acetate-salt hypertensive rats. Comparative study with verapamil. ( Duarte, J; Galisteo, M; García-Saura, MF; Jiménez, R; Vargas, F; Villar, IC; Wangensteen, R; Zarzuelo, A, 2004) |
| "Myocardial infarction is usually induced in small animals by means of invasive procedures: the aim of this study was to cause heart necrosis lesions by non-invasive means." | 1.32 | Myocardial infarction non-invasively induced in rabbits by administering isoproterenol and vasopressin: protective effects exerted by verapamil. ( Bertolini, B; Bonacina, E; Brenna, S; Pinelli, A; Tomasoni, L; Trivulzio, S; Vignati, S, 2004) |
| "Verapamil was administered at a loading dose of 0." | 1.31 | Profibrillatory effects of verapamil but not of digoxin in the goat model of atrial fibrillation. ( Allessie, MA; Duytschaever, MF; Garratt, CJ, 2000) |
| " The dose-response curve for NE (0." | 1.31 | Lead-cadmium interaction effect on the responsiveness of rat mesenteric vessels to norepinephrine and angiotensin II. ( Andrzejak, R; Skoczyńska, A; Wróbel, J, 2001) |
| "Verapamil was given in drinking water (1 gm/l) continuously from the day of infection for a total of 120 days." | 1.31 | Cardioprotective effects of verapamil on myocardial structure and function in a murine model of chronic Trypanosoma cruzi infection (Brazil Strain): an echocardiographic study. ( Chandra, M; Dominguez-Rosales, JA; Factor, SM; Jelicks, LA; Morris, SA; Petkova, SB; Rojkind, M; Shirani, J; Shtutin, V; Tanowitz, HB; Weiss, LM; Wittner, M, 2002) |
| "Intensity of catalepsy was predicted by dopamine D1, D2, and mACh receptor occupancies with the dynamic model which had already been constructed and was compared with the observed values." | 1.30 | Catalepsy induced by calcium channel blockers in mice. ( Haraguchi, K; Iga, T; Ito, K; Kotaki, H; Sawada, Y, 1998) |
| "Bupivacaine is a local anesthetic frequently used in clinical practice, and cardiotoxicity is one of its severe side effects." | 1.30 | The effects of verapamil and nimodipine on bupivacaine-induced cardiotoxicity in rats: an in vivo and in vitro study. ( Adsan, H; Onaran, O; Tulunay, M, 1998) |
| "Verapamil has been found to be protective against crystal deposition." | 1.30 | Limitation of shockwave-induced enhanced crystal deposition in traumatized tissue by verapamil in rabbit model. ( Akbay, C; Bakir, K; Korkmaz, C; Sarica, K; Sayin, N; Topçu, O; Yağci, F, 1999) |
| "Verapamil toxicity was produced in all animals following an average dose of 1." | 1.29 | Hemodynamic effects of 3,4-diaminopyridine in a swine model of verapamil toxicity. ( Martin, TG; Menegazzi, JJ; Plewa, MC; Seaberg, DC; Wolfson, AB, 1994) |
| "Trifluoperazine was less effective against acetylcholine-induced tone in sensitized, as compared to untreated, trachea." | 1.29 | Effects of two Ca2+ modulators in normal and albumin-sensitized guinea-pig trachea. ( De Jonckheere, S; McCaig, D, 1993) |
| "Cyproheptadine and verapamil were not effective in reversing chloroquine resistance and probable drug toxicity was observed with these drugs in combination with chloroquine." | 1.29 | Reversal of Plasmodium falciparum resistance to chloroquine in Panamanian Aotus monkeys. ( Kyle, DE; Milhous, WK; Rossan, RN, 1993) |
| "To further assess the effect of Trypanosoma cruzi infection on the microcirculation, we examined the cremaster microvascular model in CD-1 male mice infected with the Brazil strain at 20-25 days postinfection." | 1.29 | Compromised microcirculation in acute murine Trypanosoma cruzi infection. ( Chen, B; Factor, SM; Kaul, DK; Morris, SA; Tanowitz, HB; Weiss, LM; Wittner, M, 1996) |
| " The rats were observed for toxic signs and survival over a period of 15 days." | 1.29 | Reversal of acute theophylline toxicity by calcium channel blockers in dogs and rats. ( Alleva, FR; Balazs, T; Joseph, X; Vick, JA; Whitehurst, VE; Zhang, J, 1996) |
| "Verapamil is a calcium antagonist that has been shown to modulate wound healing through multiple mechanisms." | 1.29 | The effects of subconjunctival verapamil on filtering blebs in rabbits. ( Agarwala, A; Edward, DP; Gupta, B; Moy, JJ, 1996) |
| "Verapamil overdose, because of its frequency and severity, represents a significant problem for the emergency physician." | 1.29 | Cardiac dysrhythmias in severe verapamil overdose: characterization with a canine model. ( Koury, SI; Stone, CK; Thomas, SH, 1996) |
| "When verapamil was added to the treatment regimen of those animals bearing the 8226/C1N xenografts, there was a 179% increase in their life span (P < 0." | 1.29 | Severe combined immunodeficiency (SCID) mouse modeling of P-glycoprotein chemosensitization in multidrug-resistant human myeloma xenografts. ( Bellamy, WT; Dalton, WS; Grogan, TM; Huizenga, E; Odeleye, A; Weinstein, RS, 1995) |
| "Verapamil was given in the drinking water and the average dose calculated from the amount of drinking was 4." | 1.28 | [Effects of verapamil on cyclosporine. A (CsA)-induced nephropathy in ischemic kidney model in rats: changes in systemic hemodynamics and hepatic and renal microsomal cytochrome P-450]. ( Kawashima, H; Kim, T; Kishimoto, T; Kusunose, E; Maekawa, T; Nakatani, T; Ohyama, A; Sakamoto, W; Tsujino, T; Yoshimura, R, 1991) |
| "In previous work, we have shown that the chronic administration of verapamil, a calcium channel blocker, ameliorated the mortality, pathology, and biochemical alterations associated with acute murine Chagas' disease." | 1.28 | Effect of verapamil on the development of chronic experimental Chagas' disease. ( Bilezikian, JP; Factor, SM; Morris, SA; Tanowitz, HB; Weiss, LM; Wittner, M, 1989) |
| "Pretreatment with verapamil reduced the size of these subendocardial infarcts from 34 +/- 8 to 8 +/- 3% of the ischemic circumflex vascular bed at risk (identified by postmortem perfusion of the previously occluded and unoccluded arteries with different dyes)." | 1.27 | Verapamil in two reperfusion models of myocardial infarction. Temporary protection of severely ischemic myocardium without limitation of ultimate infarct size. ( Jennings, RB; Reimer, KA, 1984) |
| "Verapamil was more active than nifedipine in both models." | 1.27 | Evaluation of cardiac anoxia and ischemia models in the rat using calcium antagonists. ( Jacobs, LW; Rosenberger, LB; Stanton, HC, 1984) |
| " At a dosage of 20 mg/kg/day, drug therapy in each case significantly prolonged the functional ability of the dystrophic chickens as quantitated regularly by a standardized test for righting ability." | 1.27 | In vivo effects of three calcium blockers on chickens with inherited muscular dystrophy. ( Heffner, RR; Hudecki, MS; Pollina, CM, 1984) |
| "When the mural thrombus was removed from 14 grafts, a median 73% of the platelets were located in the interface between thrombus and graft." | 1.27 | Comparison of the antithrombotic action of calcium antagonist drugs with dipyridamole in dogs. ( Chesebro, JH; Dewanjee, MK; Fuster, V; Kaye, MP; Pumphrey, CW; Vlietstra, RE, 1983) |
| "When used in conjunction with raw arrhythmia data, comprehensive drug dose ranges, and appropriate parametric statistical tests, arrhythmia scores facilitate the quantification of arrhythmias." | 1.27 | Quantification of arrhythmias using scoring systems: an examination of seven scores in an in vivo model of regional myocardial ischaemia. ( Curtis, MJ; Walker, MJ, 1988) |
| "Ibuprofen and verapamil treatment resulted in less myocardial damage after 48 h than placebo treatment but the differences were generally not statistically significant." | 1.27 | Evaluation of a rat model for assessing interventions to salvage ischaemic myocardium: effects of ibuprofen and verapamil. ( Evans, RG; Fischer, VW; Kulevich, J; Mueller, HS; Val-Mejias, JE, 1985) |
| " Nicardipine given by three different dosing schedules to baboons markedly limited myocardial infarction over a 6 h period of LAD occlusion." | 1.27 | Nicardipine in models of myocardial infarction. ( Alps, BJ; Calder, C; Wilson, A, 1985) |
| "The incidence of ventricular arrhythmias was increased by aprindine (from 1 in 11 to 8 in 11 dogs), decresed by verapamil (from 3 in 7 to 0 in 7 dogs) and was not changes by quinidine or isoproterenol." | 1.26 | Effect of drugs on conduction delay and incidence of ventricular arrhythmias induced by acute coronary occlusion in dogs. ( Elharrar, V; Gaum, WE; Zipes, DP, 1977) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 56 (20.44) | 18.7374 |
| 1990's | 61 (22.26) | 18.2507 |
| 2000's | 65 (23.72) | 29.6817 |
| 2010's | 79 (28.83) | 24.3611 |
| 2020's | 13 (4.74) | 2.80 |
| Authors | Studies |
|---|---|
| Chong, CR | 1 |
| Chen, X | 3 |
| Shi, L | 1 |
| Liu, JO | 1 |
| Sullivan, DJ | 1 |
| Avdeef, A | 1 |
| Tam, KY | 1 |
| Redondo, M | 1 |
| Zarruk, JG | 1 |
| Ceballos, P | 1 |
| Pérez, DI | 1 |
| Pérez, C | 1 |
| Perez-Castillo, A | 1 |
| Moro, MA | 1 |
| Brea, J | 1 |
| Val, C | 1 |
| Cadavid, MI | 1 |
| Loza, MI | 2 |
| Campillo, NE | 1 |
| Martínez, A | 1 |
| Gil, C | 1 |
| Więckowska, A | 1 |
| Więckowski, K | 1 |
| Bajda, M | 1 |
| Brus, B | 1 |
| Sałat, K | 1 |
| Czerwińska, P | 1 |
| Gobec, S | 1 |
| Filipek, B | 1 |
| Malawska, B | 1 |
| Papadopoulou, MV | 1 |
| Bloomer, WD | 1 |
| Rosenzweig, HS | 1 |
| O'Shea, IP | 1 |
| Wilkinson, SR | 1 |
| Kaiser, M | 1 |
| Chatelain, E | 1 |
| Ioset, JR | 1 |
| Shouksmith, AE | 1 |
| Shah, F | 1 |
| Grimard, ML | 1 |
| Gawel, JM | 1 |
| Raouf, YS | 1 |
| Geletu, M | 1 |
| Berger-Becvar, A | 1 |
| de Araujo, ED | 1 |
| Luchman, HA | 1 |
| Heaton, WL | 1 |
| Bakhshinyan, D | 1 |
| Adile, AA | 1 |
| Venugopal, C | 1 |
| O'Hare, T | 1 |
| Deininger, MW | 1 |
| Singh, SK | 1 |
| Konieczny, SF | 1 |
| Weiss, S | 1 |
| Fishel, ML | 1 |
| Gunning, PT | 1 |
| Solinski, HJ | 1 |
| Dranchak, P | 1 |
| Oliphant, E | 1 |
| Gu, X | 2 |
| Earnest, TW | 1 |
| Braisted, J | 1 |
| Inglese, J | 1 |
| Hoon, MA | 1 |
| Xue, ST | 1 |
| Zhang, L | 3 |
| Xie, ZS | 1 |
| Jin, J | 1 |
| Guo, HF | 1 |
| Yi, H | 1 |
| Liu, ZY | 1 |
| Li, ZR | 1 |
| Abrams, RPM | 1 |
| Yasgar, A | 1 |
| Teramoto, T | 1 |
| Lee, MH | 2 |
| Dorjsuren, D | 1 |
| Eastman, RT | 1 |
| Malik, N | 1 |
| Zakharov, AV | 1 |
| Li, W | 2 |
| Bachani, M | 1 |
| Brimacombe, K | 1 |
| Steiner, JP | 1 |
| Hall, MD | 1 |
| Balasubramanian, A | 1 |
| Jadhav, A | 1 |
| Padmanabhan, R | 1 |
| Simeonov, A | 1 |
| Nath, A | 1 |
| Shen, S | 1 |
| Picci, C | 1 |
| Ustinova, K | 1 |
| Benoy, V | 1 |
| Kutil, Z | 1 |
| Zhang, G | 2 |
| Tavares, MT | 1 |
| Pavlíček, J | 1 |
| Zimprich, CA | 1 |
| Robers, MB | 1 |
| Van Den Bosch, L | 1 |
| Bařinka, C | 1 |
| Langley, B | 1 |
| Kozikowski, AP | 1 |
| Turcu, AL | 1 |
| Companys-Alemany, J | 1 |
| Phillips, MB | 1 |
| Patel, DS | 1 |
| Griñán-Ferré, C | 1 |
| Brea, JM | 1 |
| Pérez, B | 1 |
| Soto, D | 1 |
| Sureda, FX | 1 |
| Kurnikova, MG | 1 |
| Johnson, JW | 1 |
| Pallàs, M | 1 |
| Vázquez, S | 1 |
| Ang, CW | 1 |
| Lee, BM | 1 |
| Jackson, CJ | 1 |
| Wang, Y | 6 |
| Franzblau, SG | 1 |
| Francisco, AF | 1 |
| Kelly, JM | 1 |
| Bernhardt, PV | 1 |
| Tan, L | 1 |
| West, NP | 1 |
| Sykes, ML | 1 |
| Hinton, AO | 1 |
| Bolisetti, R | 1 |
| Avery, VM | 1 |
| Cooper, MA | 1 |
| Blaskovich, MAT | 1 |
| Wu, X | 2 |
| Hussain, M | 1 |
| Syed, SK | 1 |
| Saadullah, M | 1 |
| Alqahtani, AM | 1 |
| Alqahtani, T | 1 |
| Aldahish, A | 1 |
| Fatima, M | 1 |
| Shaukat, S | 1 |
| Hussain, L | 1 |
| Jamil, Q | 1 |
| Mukhtar, I | 1 |
| Khan, KU | 1 |
| Zeng, LH | 1 |
| Abdalla, N | 1 |
| Ortiz-Romero, P | 1 |
| Rodriguez-Rovira, I | 1 |
| Pérez-Jurado, LA | 1 |
| Egea, G | 1 |
| Campuzano, V | 1 |
| Boboc, IKS | 1 |
| Cojocaru, A | 1 |
| Nedelea, G | 1 |
| Catalin, B | 1 |
| Bogdan, M | 1 |
| Calina, D | 1 |
| Song, Z | 1 |
| Li, S | 2 |
| Zhang, C | 2 |
| Yuan, L | 1 |
| Han, L | 2 |
| Liu, Y | 2 |
| Bobenko, AI | 1 |
| Heller, S | 1 |
| Schmitt, N | 1 |
| Cherdtrakulkiat, R | 1 |
| Lawung, R | 1 |
| Nabu, S | 1 |
| Tantimavanich, S | 1 |
| Sinthupoom, N | 1 |
| Prachayasittikul, S | 1 |
| Prachayasittikul, V | 1 |
| Zhang, B | 1 |
| Wu, C | 1 |
| Zhang, Z | 2 |
| Yan, K | 1 |
| Li, C | 2 |
| Li, Y | 5 |
| Li, L | 4 |
| Zheng, C | 1 |
| Xiao, Y | 1 |
| He, D | 1 |
| Zhao, F | 1 |
| Su, JF | 1 |
| Lun, SM | 1 |
| Hou, YJ | 1 |
| Duan, LJ | 1 |
| Wang, NC | 1 |
| Shen, FF | 1 |
| Zhang, YW | 1 |
| Gao, ZW | 1 |
| Li, J | 6 |
| Du, XJ | 1 |
| Zhou, FY | 1 |
| Yin, Z | 1 |
| Zhu, J | 2 |
| Yan, D | 1 |
| Lou, H | 1 |
| Yu, H | 3 |
| Feng, C | 1 |
| Wang, Z | 1 |
| Hu, X | 1 |
| Li, Z | 2 |
| Shen, Y | 1 |
| Hu, D | 2 |
| Chen, H | 1 |
| Duan, Y | 1 |
| Zhi, D | 1 |
| Zou, M | 2 |
| Zhao, Z | 1 |
| Zhang, X | 4 |
| Yang, X | 2 |
| Zhang, J | 5 |
| Wang, H | 2 |
| Popović, KJ | 1 |
| Popović, DJ | 1 |
| Miljković, D | 1 |
| Lalošević, D | 1 |
| Čapo, I | 1 |
| Popović, JK | 1 |
| Liu, M | 1 |
| Song, H | 2 |
| Xing, Z | 1 |
| Lu, G | 1 |
| Chen, D | 1 |
| Valentini, AM | 1 |
| Di Pinto, F | 1 |
| Coletta, S | 1 |
| Guerra, V | 1 |
| Armentano, R | 1 |
| Caruso, ML | 1 |
| Gong, J | 2 |
| Wang, N | 1 |
| Bian, L | 1 |
| Wang, M | 1 |
| Ye, M | 1 |
| Wen, N | 1 |
| Fu, M | 1 |
| Fan, W | 1 |
| Meng, Y | 1 |
| Dong, G | 1 |
| Lin, XH | 1 |
| Liu, HH | 1 |
| Gao, DM | 1 |
| Cui, JF | 1 |
| Ren, ZG | 1 |
| Chen, RX | 1 |
| Önal, B | 1 |
| Özen, D | 1 |
| Demir, B | 1 |
| Akkan, AG | 1 |
| Özyazgan, S | 1 |
| Payette, G | 1 |
| Geoffroy, V | 1 |
| Martineau, C | 1 |
| Villemur, R | 1 |
| Jameel, T | 1 |
| Baig, M | 1 |
| Gazzaz, ZJ | 1 |
| Tashkandi, JM | 1 |
| Al Alhareth, NS | 1 |
| Khan, SA | 1 |
| Butt, NS | 1 |
| Wang, J | 5 |
| Geng, Y | 1 |
| Zhang, Y | 6 |
| Wang, X | 4 |
| Liu, J | 4 |
| Basit, A | 1 |
| Miao, T | 1 |
| Liu, W | 1 |
| Jiang, W | 1 |
| Yu, ZY | 1 |
| Wu, L | 2 |
| Qu, B | 1 |
| Sun, JX | 1 |
| Cai, AL | 1 |
| Xie, LM | 1 |
| Groeneveld, J | 1 |
| Ho, SL | 1 |
| Mackensen, A | 1 |
| Mohtadi, M | 1 |
| Laepple, T | 1 |
| Genovesi, S | 1 |
| Nava, E | 1 |
| Bartolucci, C | 1 |
| Severi, S | 1 |
| Vincenti, A | 1 |
| Contaldo, G | 1 |
| Bigatti, G | 1 |
| Ciurlino, D | 1 |
| Bertoli, SV | 1 |
| Slovak, JE | 1 |
| Hwang, JK | 1 |
| Rivera, SM | 1 |
| Villarino, NF | 1 |
| Cao, G | 1 |
| Ling, M | 1 |
| Ji, J | 1 |
| Zhao, D | 1 |
| Sha, Y | 1 |
| Gao, X | 1 |
| Liang, C | 2 |
| Guo, Q | 1 |
| Zhou, C | 1 |
| Ma, Z | 1 |
| Xu, J | 2 |
| Wang, C | 3 |
| Zhao, W | 1 |
| Xia, X | 1 |
| Jiang, Y | 1 |
| Peng, J | 1 |
| Jia, Z | 1 |
| Li, F | 1 |
| Mo, J | 1 |
| Zhang, S | 2 |
| Li, X | 1 |
| Huang, T | 1 |
| Zhu, Q | 1 |
| Wang, S | 1 |
| Ge, RS | 1 |
| Fortunato, G | 1 |
| Lin, J | 2 |
| Agarwal, PK | 1 |
| Kohen, A | 1 |
| Singh, P | 1 |
| Cheatum, CM | 1 |
| Zhu, D | 1 |
| Hayman, A | 1 |
| Kebede, B | 1 |
| Stewart, I | 1 |
| Chen, G | 1 |
| Frew, R | 1 |
| Guo, X | 1 |
| Gong, Q | 1 |
| Borowiec, J | 1 |
| Han, S | 1 |
| Zhang, M | 2 |
| Willis, M | 1 |
| Kreouzis, T | 1 |
| Yu, K | 1 |
| Chirvony, VS | 1 |
| Sekerbayev, KS | 1 |
| Pérez-Del-Rey, D | 1 |
| Martínez-Pastor, JP | 1 |
| Palazon, F | 1 |
| Boix, PP | 1 |
| Taurbayev, TI | 1 |
| Sessolo, M | 1 |
| Bolink, HJ | 1 |
| Lu, M | 1 |
| Lan, Y | 1 |
| Xiao, J | 1 |
| Song, M | 1 |
| Chen, C | 1 |
| Huang, Q | 1 |
| Cao, Y | 1 |
| Ho, CT | 1 |
| Qi, B | 1 |
| Wang, Q | 2 |
| Zhang, W | 1 |
| Fang, L | 1 |
| Xie, CL | 1 |
| Chen, R | 1 |
| Yang, S | 1 |
| Xia, JM | 1 |
| Zhang, GY | 1 |
| Chen, CH | 1 |
| Yang, XW | 1 |
| Domenech-Ximenos, B | 1 |
| Garza, MS | 1 |
| Prat-González, S | 1 |
| Sepúlveda-Martínez, Á | 1 |
| Crispi, F | 1 |
| Perea, RJ | 1 |
| Garcia-Alvarez, A | 1 |
| Sitges, M | 1 |
| Kalumpha, M | 1 |
| Guyo, U | 1 |
| Zinyama, NP | 1 |
| Vakira, FM | 1 |
| Nyamunda, BC | 1 |
| Varga, M | 1 |
| Drácz, L | 1 |
| Kolbenheyer, E | 1 |
| Varga, F | 1 |
| Patai, ÁV | 1 |
| Solymosi, N | 1 |
| Patai, Á | 1 |
| Kiss, J | 1 |
| Gaál, V | 1 |
| Nyul, Z | 1 |
| Mosdósi, B | 1 |
| Valdez, M | 1 |
| Moosavi, L | 1 |
| Heidari, A | 1 |
| Novakovic-Agopian, T | 1 |
| Kornblith, E | 1 |
| Abrams, G | 1 |
| McQuaid, JR | 1 |
| Posecion, L | 1 |
| Burciaga, J | 1 |
| D'Esposito, M | 1 |
| Chen, AJW | 1 |
| Samy El Gendy, NM | 1 |
| Wesolowska, P | 1 |
| Georg, D | 1 |
| Lechner, W | 1 |
| Kazantsev, P | 1 |
| Bokulic, T | 1 |
| Tedgren, AC | 1 |
| Adolfsson, E | 1 |
| Campos, AM | 1 |
| Alves, VGL | 1 |
| Suming, L | 1 |
| Hao, W | 1 |
| Ekendahl, D | 1 |
| Koniarova, I | 1 |
| Bulski, W | 1 |
| Chelminski, K | 1 |
| Samper, JLA | 1 |
| Vinatha, SP | 1 |
| Rakshit, S | 1 |
| Siri, S | 1 |
| Tomsejm, M | 1 |
| Tenhunen, M | 1 |
| Povall, J | 1 |
| Kry, SF | 1 |
| Followill, DS | 1 |
| Thwaites, DI | 1 |
| Izewska, J | 1 |
| Kang, JH | 1 |
| Yoon, Y | 1 |
| Song, J | 1 |
| Van de Winckel, A | 1 |
| Gauthier, L | 1 |
| Chao, CT | 1 |
| Lee, YH | 1 |
| Li, CM | 1 |
| Han, DS | 1 |
| Huang, JW | 1 |
| Huang, KC | 1 |
| Ni, L | 1 |
| Güttinger, R | 1 |
| Triana, CA | 1 |
| Spingler, B | 1 |
| Baldridge, KK | 1 |
| Patzke, GR | 1 |
| Shen, X | 2 |
| Wang, B | 1 |
| Xie, S | 1 |
| Deng, W | 1 |
| Wu, D | 1 |
| Zhang, Q | 1 |
| Voskamp, BJ | 1 |
| Peelen, MJCS | 1 |
| Ravelli, ACJ | 1 |
| van der Lee, R | 1 |
| Mol, BWJ | 1 |
| Pajkrt, E | 1 |
| Ganzevoort, W | 1 |
| Kazemier, BM | 1 |
| Tibrewala, R | 1 |
| Bahroos, E | 1 |
| Mehrabian, H | 1 |
| Foreman, SC | 1 |
| Link, TM | 1 |
| Pedoia, V | 1 |
| Majumdar, S | 1 |
| Jablonski, CL | 1 |
| Leonard, C | 1 |
| Salo, P | 1 |
| Krawetz, RJ | 1 |
| Yoon, N | 1 |
| Hong, SN | 1 |
| Cho, JG | 1 |
| Jeong, HK | 1 |
| Lee, KH | 1 |
| Park, HW | 1 |
| Barman, S | 1 |
| Konai, MM | 1 |
| Samaddar, S | 1 |
| Haldar, J | 1 |
| Mohamed, HSH | 1 |
| Li, CF | 1 |
| Hu, ZY | 1 |
| Deng, Z | 1 |
| Chen, LH | 1 |
| Su, BL | 1 |
| Chu, K | 3 |
| Liu, YP | 1 |
| Li, YB | 1 |
| Zhang, H | 1 |
| Xu, C | 1 |
| Zou, Z | 1 |
| Wu, Z | 1 |
| Xia, Y | 1 |
| Zhao, P | 1 |
| Wang, HT | 1 |
| de Biase, S | 1 |
| Pellitteri, G | 1 |
| Gigli, GL | 1 |
| Valente, M | 1 |
| Qiu, L | 1 |
| Ouyang, H | 1 |
| Li, T | 1 |
| Xu, W | 1 |
| van Weperen, VYH | 1 |
| Bossu, A | 1 |
| Vos, MA | 2 |
| Hao, P | 2 |
| Yang, D | 1 |
| Feng, S | 1 |
| Peng, B | 1 |
| Appelhans, D | 1 |
| Zhang, T | 1 |
| Zan, X | 1 |
| Nikpour, M | 1 |
| Sharafi, A | 1 |
| Hamidi, M | 1 |
| Andalib, S | 1 |
| Di Diego, JM | 1 |
| Patocskai, B | 1 |
| Barajas-Martinez, H | 1 |
| Borbáth, V | 1 |
| Ackerman, MJ | 1 |
| Burashnikov, A | 1 |
| Clatot, J | 1 |
| Li, GR | 1 |
| Robinson, VM | 1 |
| Antzelevitch, C | 1 |
| Hsu, AC | 1 |
| Gou, Y | 1 |
| Sun, W | 1 |
| Wang, F | 1 |
| Li, P | 1 |
| Ahmed, HA | 1 |
| Ismael, S | 1 |
| Mirzahosseini, G | 1 |
| Ishrat, T | 1 |
| Watanabe, I | 1 |
| Gettes, LS | 1 |
| Ghosal, S | 1 |
| Bang, E | 1 |
| Yue, W | 1 |
| Hare, BD | 1 |
| Lepack, AE | 1 |
| Girgenti, MJ | 1 |
| Duman, RS | 1 |
| Jiang, M | 1 |
| Chen, J | 1 |
| Fan, G | 1 |
| Zhu, Y | 1 |
| Li, M | 1 |
| Lv, D | 1 |
| Sun, X | 1 |
| Hu, J | 1 |
| Sagawa, H | 1 |
| Hoshino, S | 1 |
| Yoshioka, K | 1 |
| Ding, WG | 1 |
| Omatsu-Kanbe, M | 1 |
| Nakagawa, M | 1 |
| Maruo, Y | 1 |
| Matsuura, H | 1 |
| Hafez, HM | 1 |
| Ibrahim, MA | 1 |
| Zedan, MZ | 1 |
| Hassan, M | 1 |
| Hassanein, H | 1 |
| Fu, YS | 1 |
| Lue, SI | 1 |
| Lin, SY | 1 |
| Luo, CL | 1 |
| Chou, CC | 1 |
| Weng, CF | 1 |
| Zhao, M | 1 |
| Tang, Y | 1 |
| Ernst, PJ | 1 |
| Kahn-Krell, A | 1 |
| Fan, C | 1 |
| Pretorius, D | 1 |
| Zhu, H | 1 |
| Lou, X | 1 |
| Zhou, L | 1 |
| Zhu, W | 1 |
| Cao, H | 1 |
| Ma, J | 1 |
| Gao, Y | 1 |
| Zhang, F | 1 |
| Chu, L | 1 |
| Calcinaghi, N | 1 |
| Wyss, MT | 1 |
| Jolivet, R | 1 |
| Singh, A | 1 |
| Keller, AL | 1 |
| Winnik, S | 1 |
| Fritschy, JM | 1 |
| Buck, A | 1 |
| Matter, CM | 1 |
| Weber, B | 1 |
| Mehta, DC | 1 |
| Short, JL | 1 |
| Nicolazzo, JA | 1 |
| Stöhr, A | 1 |
| Friedrich, FW | 1 |
| Flenner, F | 1 |
| Geertz, B | 1 |
| Eder, A | 1 |
| Schaaf, S | 1 |
| Hirt, MN | 1 |
| Uebeler, J | 1 |
| Schlossarek, S | 1 |
| Carrier, L | 1 |
| Hansen, A | 1 |
| Eschenhagen, T | 1 |
| Zhou, P | 1 |
| Zhang, SM | 1 |
| Wang, QL | 1 |
| Wu, Q | 1 |
| Chen, M | 1 |
| Pei, JM | 1 |
| Ribeiro-Filho, J | 1 |
| Calheiros, AS | 1 |
| Vieira-de-Abreu, A | 1 |
| de Carvalho, KI | 1 |
| da Silva Mendes, D | 1 |
| Melo, CB | 1 |
| Martins, MA | 1 |
| da Silva Dias, C | 1 |
| Piuvezam, MR | 1 |
| Bozza, PT | 1 |
| Speerschneider, T | 1 |
| Thomsen, MB | 1 |
| Singh, DP | 1 |
| Chopra, K | 1 |
| Akindele, AJ | 1 |
| Adeneye, AA | 1 |
| Olatoye, F | 1 |
| Benebo, AS | 1 |
| Ma, A | 1 |
| Chen, Y | 1 |
| Yuan, W | 1 |
| Takamatsu, A | 1 |
| Ohkawara, B | 1 |
| Ito, M | 1 |
| Masuda, A | 1 |
| Sakai, T | 1 |
| Ishiguro, N | 1 |
| Ohno, K | 1 |
| Doorduin, J | 1 |
| de Vries, EF | 1 |
| Dierckx, RA | 1 |
| Klein, HC | 1 |
| Uchida, Y | 1 |
| Ohtsuki, S | 1 |
| Terasaki, T | 1 |
| Gupta, S | 1 |
| Tyagi, S | 1 |
| Bishai, WR | 1 |
| Yang, SY | 2 |
| Yang, JY | 3 |
| Hsiao, YC | 2 |
| Zhang, JW | 1 |
| Zhang, GX | 1 |
| Chen, HL | 1 |
| Liu, GL | 1 |
| Owusu, L | 1 |
| Wang, YX | 1 |
| Wang, GY | 1 |
| Xu, CM | 1 |
| Rhodes, J | 1 |
| Saxena, D | 1 |
| Gittes, GK | 1 |
| Potoka, DA | 1 |
| Fan, Q | 1 |
| Chen, SL | 1 |
| Ma, H | 1 |
| Im, W | 1 |
| Ban, JJ | 1 |
| Chung, JY | 1 |
| Lee, ST | 1 |
| Kim, M | 1 |
| Rha, EY | 1 |
| Kim, YH | 1 |
| Kim, TJ | 1 |
| Yoo, G | 1 |
| Rhie, JW | 1 |
| Kim, HJ | 1 |
| Park, IK | 1 |
| Tulgar, S | 1 |
| Kose, HC | 1 |
| Demir Piroglu, I | 1 |
| Karakilic, E | 1 |
| Ates, NG | 1 |
| Demir, A | 1 |
| Gergerli, R | 1 |
| Guven, S | 1 |
| Piroglu, MD | 1 |
| Getiye, Y | 1 |
| Tolessa, T | 1 |
| Engidawork, E | 1 |
| Kitsou, C | 1 |
| Kosmas, I | 1 |
| Lazaros, L | 1 |
| Tzallas, C | 1 |
| Tinelli, A | 1 |
| Mynbaev, O | 1 |
| Prapas, N | 1 |
| Prapas, I | 1 |
| Dalkalitsis, A | 1 |
| Georgiou, I | 1 |
| Ashkani-Esfahani, S | 1 |
| Hosseinabadi, OK | 1 |
| Moezzi, P | 1 |
| Moafpourian, Y | 1 |
| Kardeh, S | 1 |
| Rafiee, S | 1 |
| Fatheazam, R | 1 |
| Noorafshan, A | 1 |
| Nadimi, E | 1 |
| Mehrvarz, S | 1 |
| Khoshneviszadeh, M | 2 |
| De Mello, W | 1 |
| Chuang, SS | 1 |
| Sokhanenkova, AE | 1 |
| Sokhanenkov, MIu | 1 |
| Afanas'eva, EIu | 1 |
| Arzamastsev, EV | 1 |
| Perez, E | 3 |
| Bania, TC | 3 |
| Medlej, K | 2 |
| Chu, J | 3 |
| Matsumura, CY | 1 |
| Pertille, A | 1 |
| Albuquerque, TC | 1 |
| Santo Neto, H | 1 |
| Marques, MJ | 1 |
| Ishiguro, YS | 1 |
| Honjo, H | 1 |
| Opthof, T | 1 |
| Okuno, Y | 1 |
| Nakagawa, H | 1 |
| Yamazaki, M | 1 |
| Harada, M | 1 |
| Takanari, H | 1 |
| Suzuki, T | 1 |
| Morishima, M | 1 |
| Sakuma, I | 1 |
| Kamiya, K | 1 |
| Kodama, I | 1 |
| Dosdall, DJ | 1 |
| Graudins, A | 2 |
| Ertunc, M | 1 |
| Sara, Y | 1 |
| Korkusuz, P | 1 |
| Onur, R | 1 |
| Patel, KJ | 1 |
| Tannock, IF | 1 |
| Sun, Y | 1 |
| Liou, B | 1 |
| Quinn, B | 1 |
| Ran, H | 1 |
| Xu, YH | 1 |
| Grabowski, GA | 1 |
| Chen, L | 2 |
| Yang, J | 1 |
| Davey, AK | 1 |
| Chen, YX | 1 |
| Wang, JP | 1 |
| Liu, XQ | 1 |
| Kurola, J | 1 |
| Leppikangas, H | 1 |
| Magga, J | 1 |
| Lindgren, L | 1 |
| Kiviniemi, V | 1 |
| Rutanen, J | 1 |
| Ruokonen, E | 1 |
| Kijtawornrat, A | 1 |
| Ziolo, MT | 1 |
| Nishijima, Y | 1 |
| Roche, BM | 1 |
| Hamlin, RL | 1 |
| Mottram, AR | 1 |
| Bryant, SM | 1 |
| Aks, SE | 1 |
| Alcalai, R | 1 |
| Wakimoto, H | 1 |
| Arad, M | 1 |
| Planer, D | 1 |
| Konno, T | 1 |
| Wang, L | 1 |
| Seidman, JG | 1 |
| Seidman, CE | 1 |
| Berul, CI | 1 |
| Xiao, D | 1 |
| Longo, LD | 1 |
| Hanafy, S | 1 |
| El-Kadi, AO | 1 |
| Jamali, F | 2 |
| Huang, CY | 1 |
| Kumfu, S | 3 |
| Chattipakorn, S | 3 |
| Srichairatanakool, S | 1 |
| Settakorn, J | 1 |
| Fucharoen, S | 3 |
| Chattipakorn, N | 3 |
| Kalonia, H | 1 |
| Kumar, P | 1 |
| Kumar, A | 1 |
| Otto-Duessel, M | 1 |
| Brewer, C | 1 |
| Wood, JC | 1 |
| Bao, L | 1 |
| Haque, A | 1 |
| Jackson, K | 1 |
| Hazari, S | 1 |
| Moroz, K | 1 |
| Jetly, R | 1 |
| Dash, S | 1 |
| Adams, KN | 1 |
| Takaki, K | 1 |
| Connolly, LE | 1 |
| Wiedenhoft, H | 1 |
| Winglee, K | 1 |
| Humbert, O | 1 |
| Edelstein, PH | 1 |
| Cosma, CL | 1 |
| Ramakrishnan, L | 1 |
| Chen, GM | 1 |
| Hu, N | 1 |
| Liu, L | 1 |
| Xie, SS | 1 |
| Wang, P | 1 |
| Xie, L | 1 |
| Wang, GJ | 1 |
| Liu, XD | 1 |
| Louw, GE | 1 |
| Warren, RM | 1 |
| Gey van Pittius, NC | 1 |
| Leon, R | 1 |
| Jimenez, A | 1 |
| Hernandez-Pando, R | 1 |
| McEvoy, CR | 1 |
| Grobbelaar, M | 1 |
| Murray, M | 1 |
| van Helden, PD | 1 |
| Victor, TC | 1 |
| Tanriverdi, O | 1 |
| Telci, D | 1 |
| Aydin, M | 1 |
| Ekici, ID | 1 |
| Miroglu, C | 1 |
| Sarıca, K | 4 |
| Luna-Munguia, H | 1 |
| Orozco-Suarez, S | 1 |
| Rocha, L | 1 |
| Bankstahl, JP | 2 |
| Bankstahl, M | 2 |
| Kuntner, C | 2 |
| Stanek, J | 2 |
| Wanek, T | 2 |
| Meier, M | 1 |
| Ding, XQ | 1 |
| Müller, M | 2 |
| Langer, O | 2 |
| Löscher, W | 2 |
| Pingsheng, F | 1 |
| Tengyue, Z | 1 |
| Qiang, H | 1 |
| Qiang, W | 1 |
| Xin, S | 1 |
| Liting, Q | 1 |
| Shokri, A | 1 |
| Sharifi, I | 1 |
| Khamesipour, A | 1 |
| Nakhaee, N | 1 |
| Fasihi Harandi, M | 1 |
| Nosratabadi, J | 1 |
| Hakimi Parizi, M | 1 |
| Barati, M | 1 |
| Naderi, N | 1 |
| Ahmad-Molaei, L | 1 |
| Mazar-Atabaki, A | 1 |
| Ronaghi, A | 1 |
| Shirazi-zand, Z | 1 |
| Motiei-Langroudi, SM | 1 |
| Eslahkar, S | 1 |
| Baio, G | 1 |
| Fabbi, M | 1 |
| Emionite, L | 1 |
| Cilli, M | 1 |
| Salvi, S | 1 |
| Ghedin, P | 1 |
| Prato, S | 1 |
| Carbotti, G | 1 |
| Tagliafico, A | 1 |
| Truini, M | 1 |
| Neumaier, CE | 1 |
| Sauberer, M | 1 |
| Mairinger, S | 1 |
| Strommer, S | 1 |
| Wacheck, V | 1 |
| Erker, T | 1 |
| Mandade, RJ | 1 |
| Sreenivas, SA | 1 |
| Sakarkar, DM | 1 |
| Choudhury, A | 1 |
| Bania, T | 1 |
| Khakzad, MR | 1 |
| Mirsadraee, M | 1 |
| Mohammadpour, A | 1 |
| Ghafarzadegan, K | 1 |
| Hadi, R | 1 |
| Saghari, M | 1 |
| Meshkat, M | 1 |
| Stams, TR | 1 |
| Bourgonje, VJ | 1 |
| van der Heyden, MA | 1 |
| Rinker, B | 1 |
| Fink, BF | 1 |
| Stoker, AR | 1 |
| Milan, ME | 1 |
| Nelson, PT | 1 |
| Chinda, K | 1 |
| Umukoro, S | 1 |
| Bakre, TO | 1 |
| Onwuchekwa, C | 1 |
| Fujimoto, K | 1 |
| Fujii, G | 1 |
| Mutoh, M | 1 |
| Yasunaga, M | 1 |
| Tanaka, H | 1 |
| Wada, M | 1 |
| Matsunami, M | 1 |
| Miki, T | 1 |
| Nishiura, K | 1 |
| Hayashi, Y | 1 |
| Okawa, Y | 1 |
| Nishikawa, H | 1 |
| Sekiguchi, F | 1 |
| Kubo, L | 1 |
| Ozaki, T | 1 |
| Tsujiuchi, T | 1 |
| Kawabata, A | 1 |
| Chung, E | 1 |
| Garcia, F | 1 |
| Young, LD | 1 |
| Solomon, M | 1 |
| Brock, GB | 1 |
| Feng, P | 1 |
| Zhou, D | 1 |
| Zhu, JJ | 1 |
| Xu, YQ | 1 |
| He, JH | 1 |
| Yu, HP | 1 |
| Huang, CJ | 1 |
| Gao, JM | 1 |
| Dong, QX | 1 |
| Xuan, YX | 1 |
| Li, CQ | 1 |
| Fossa, AA | 1 |
| DePasquale, MJ | 1 |
| Raunig, DL | 1 |
| Avery, MJ | 1 |
| Leishman, DJ | 1 |
| Riou, LM | 1 |
| Ruiz, M | 1 |
| Rieger, JM | 1 |
| Macdonald, TL | 1 |
| Watson, DD | 1 |
| Linden, J | 1 |
| Beller, GA | 1 |
| Glover, DK | 1 |
| Davis, BJ | 1 |
| Cao, Z | 1 |
| de Gasparo, M | 1 |
| Kawachi, H | 1 |
| Cooper, ME | 1 |
| Allen, TJ | 1 |
| Gavrish, AS | 1 |
| Verbitskiĭ, VV | 1 |
| Shchul'ts, NV | 1 |
| Danilishina, MV | 1 |
| Varoni, MV | 1 |
| Palomba, D | 1 |
| Satta, M | 1 |
| Anania, V | 1 |
| Yağmurdur, MC | 1 |
| Ozdemir, A | 1 |
| Ozenç, A | 1 |
| Kilinç, K | 1 |
| Moriguchi, M | 1 |
| Niwano, S | 1 |
| Yoshizawa, N | 1 |
| Kojima, J | 1 |
| Inuo, K | 1 |
| Izumi, T | 1 |
| McNair, LL | 1 |
| Salamanca, DA | 1 |
| Khalil, RA | 1 |
| Wheeler, MT | 1 |
| Korcarz, CE | 1 |
| Collins, KA | 1 |
| Lapidos, KA | 1 |
| Hack, AA | 1 |
| Lyons, MR | 1 |
| Zarnegar, S | 1 |
| Earley, JU | 1 |
| Lang, RM | 1 |
| McNally, EM | 1 |
| De Souza, AP | 1 |
| Tanowitz, HB | 4 |
| Chandra, M | 2 |
| Shtutin, V | 2 |
| Weiss, LM | 4 |
| Morris, SA | 4 |
| Factor, SM | 4 |
| Huang, H | 1 |
| Wittner, M | 4 |
| Shirani, J | 2 |
| Jelicks, LA | 2 |
| Almond, G | 1 |
| Reffelmann, T | 1 |
| Kloner, RA | 3 |
| Galisteo, M | 1 |
| García-Saura, MF | 1 |
| Jiménez, R | 1 |
| Villar, IC | 1 |
| Wangensteen, R | 1 |
| Zarzuelo, A | 1 |
| Vargas, F | 1 |
| Duarte, J | 1 |
| Pereira, LM | 1 |
| Bezerra, DG | 1 |
| Mandarim-de-Lacerda, CA | 2 |
| Erbagci, A | 1 |
| Yağci, F | 2 |
| Bakir, K | 2 |
| Erturhan, S | 1 |
| Uçak, R | 1 |
| Mikheytseva, IN | 1 |
| Kashintseva, LT | 1 |
| Krizhanovsky, GN | 1 |
| Kopp, OP | 1 |
| Lipovetskaya, EM | 1 |
| Pinelli, A | 1 |
| Trivulzio, S | 1 |
| Tomasoni, L | 1 |
| Bertolini, B | 1 |
| Brenna, S | 1 |
| Bonacina, E | 1 |
| Vignati, S | 1 |
| Sztajnkrycer, MD | 1 |
| Bond, GR | 1 |
| Johnson, SB | 1 |
| Weaver, AL | 1 |
| Ling, S | 1 |
| Jhee, OH | 1 |
| Hong, JW | 1 |
| Om, AS | 1 |
| Lee, WS | 1 |
| Shaw, LM | 1 |
| Lee, JW | 1 |
| Kang, JS | 1 |
| Tamez, PA | 1 |
| Lantvit, D | 1 |
| Lim, E | 1 |
| Pezzuto, JM | 1 |
| Choi, JS | 1 |
| Burm, JP | 1 |
| Maeda, T | 1 |
| Lee, SM | 1 |
| Hovda, DA | 1 |
| Vallazza-Deschamps, G | 1 |
| Cia, D | 1 |
| Jellali, A | 1 |
| Duboc, A | 1 |
| Forster, V | 1 |
| Sahel, JA | 1 |
| Tessier, LH | 1 |
| Picaud, S | 1 |
| Zeytunlu, M | 1 |
| Korkut, M | 1 |
| Akgün, E | 1 |
| Firat, O | 1 |
| Aynaci, M | 1 |
| Içöz, G | 1 |
| Kiliç, M | 1 |
| Ersin, S | 1 |
| Ozütemiz, O | 1 |
| Tebbutt, S | 1 |
| Harvey, M | 1 |
| Nicholson, T | 1 |
| Cave, G | 1 |
| Tanabe, Y | 1 |
| Hatada, K | 1 |
| Naito, N | 1 |
| Aizawa, Y | 2 |
| Chinushi, M | 1 |
| Nawa, H | 1 |
| Sirmagul, B | 1 |
| Kilic, FS | 1 |
| Tunc, O | 1 |
| Yildirim, E | 1 |
| Erol, K | 1 |
| Othman, AA | 1 |
| Syed, SA | 1 |
| Newman, AH | 1 |
| Eddington, ND | 1 |
| Xu, D | 1 |
| Wu, Y | 1 |
| Liao, ZX | 1 |
| Yong, WW | 1 |
| Sourial, M | 1 |
| Farmer, PJ | 1 |
| Southwell, BR | 1 |
| Hutson, JM | 1 |
| Jiang, C | 1 |
| Fan, L | 1 |
| Zhou, Z | 1 |
| Song, B | 1 |
| Gueret, G | 1 |
| Pennec, JP | 1 |
| Arvieux, CC | 2 |
| Yokoyama, O | 1 |
| Miwa, Y | 1 |
| Oyama, N | 1 |
| Aoki, Y | 1 |
| Ito, H | 1 |
| Akino, H | 1 |
| Najafi, J | 1 |
| Rur-SC, MP | 1 |
| Barry, JD | 1 |
| Durkovich, D | 1 |
| Cantrell, L | 1 |
| Richardson, W | 1 |
| Tong, T | 1 |
| Offerman, S | 1 |
| Clark, RF | 1 |
| Tanen, DA | 2 |
| Williams, S | 1 |
| Toronyi, E | 1 |
| Weiss, EB | 1 |
| Markowicz, J | 1 |
| Barbero, L | 1 |
| Gallant, EM | 1 |
| Scannapieco, G | 1 |
| Pauletto, P | 1 |
| Semplicini, A | 1 |
| Dario, C | 1 |
| Vescovo, G | 1 |
| Mazzucato, A | 1 |
| Angelini, A | 1 |
| Pessina, AC | 1 |
| Burke, TJ | 1 |
| Arnold, PE | 1 |
| Gordon, JA | 1 |
| Bulger, RE | 1 |
| Dobyan, DC | 1 |
| Schrier, RW | 3 |
| Reimer, KA | 3 |
| Jennings, RB | 3 |
| Rosenberger, LB | 1 |
| Jacobs, LW | 1 |
| Stanton, HC | 1 |
| Hudecki, MS | 1 |
| Pollina, CM | 1 |
| Heffner, RR | 1 |
| Sekeresh, L | 1 |
| Pumphrey, CW | 2 |
| Fuster, V | 2 |
| Dewanjee, MK | 2 |
| Chesebro, JH | 1 |
| Vlietstra, RE | 2 |
| Kaye, MP | 2 |
| DeBoer, LW | 1 |
| Strauss, HW | 1 |
| Rude, RE | 1 |
| Davis, RF | 1 |
| Maroko, PR | 2 |
| Braunwald, E | 1 |
| Decorti, G | 1 |
| Bartoli Klugmann, F | 1 |
| Klugmann, S | 1 |
| Ribeiro, LG | 2 |
| Cheung, W | 1 |
| Alves Filho, G | 1 |
| Saragoça, MA | 1 |
| Ribeiro, AB | 1 |
| Ramos, OL | 1 |
| Murphy, KP | 1 |
| Vasques, EC | 1 |
| Mill, JG | 1 |
| Moysés, MR | 1 |
| da Silva, FD | 1 |
| da Costa, MB | 1 |
| Caldas, JG | 1 |
| Cabral, Ade M | 1 |
| Vassalo, DV | 1 |
| Yasuda, T | 1 |
| Gao, TL | 1 |
| Nunnally, RL | 1 |
| Bottomley, PA | 1 |
| Dersham, GH | 1 |
| Han, J | 1 |
| Haruno, A | 1 |
| Hashimoto, K | 2 |
| al-Bekairi, AM | 1 |
| al-Rajhi, AM | 1 |
| Tariq, M | 1 |
| Myrdal, PB | 1 |
| Simamora, P | 1 |
| Surakitbanharn, Y | 1 |
| Yalkowsky, SH | 1 |
| Lu, HR | 1 |
| Remeysen, P | 1 |
| De Clerck, F | 1 |
| Moreau, P | 2 |
| Takase, H | 2 |
| Küng, CF | 2 |
| van Rooijen, MM | 1 |
| Schaffner, T | 1 |
| Lüscher, TF | 2 |
| Ciulla, TA | 1 |
| Moulton, R | 1 |
| Oberoi, A | 1 |
| Miller, JW | 1 |
| Hurt, CM | 1 |
| Pelleg, A | 1 |
| Reams, GP | 1 |
| Onuaguluchi, G | 1 |
| Igbo, IN | 1 |
| Fleckenstein-Grün, G | 1 |
| Thimm, F | 1 |
| Czirfuzs, A | 1 |
| Matyas, S | 1 |
| Frey, M | 1 |
| Plewa, MC | 1 |
| Martin, TG | 1 |
| Menegazzi, JJ | 1 |
| Seaberg, DC | 1 |
| Wolfson, AB | 1 |
| Kline, JA | 1 |
| Tomaszewski, CA | 1 |
| Schroeder, JD | 1 |
| Raymond, RM | 1 |
| McCaig, D | 1 |
| De Jonckheere, S | 1 |
| Finkel, MS | 1 |
| Shen, L | 1 |
| Oddis, CV | 1 |
| Romeo, RC | 1 |
| Kobayashi, A | 1 |
| Nishiyama, T | 1 |
| Ikegaya, T | 1 |
| Kaneko, M | 1 |
| Yamazaki, N | 1 |
| Kyle, DE | 1 |
| Milhous, WK | 1 |
| Rossan, RN | 1 |
| Lauerma, K | 1 |
| Saeed, M | 1 |
| Wendland, MF | 1 |
| Derugin, N | 1 |
| Yu, KK | 1 |
| Higgins, CB | 1 |
| Beaughard, M | 1 |
| Brasset, M | 1 |
| John, G | 1 |
| Massingham, R | 1 |
| Chagas, AC | 1 |
| Pileggi, F | 1 |
| Lopes, EA | 1 |
| Da-Luz, PL | 1 |
| Schachter, EN | 1 |
| Zuskin, E | 1 |
| Buck, MG | 1 |
| Maayani, S | 1 |
| Marom, Z | 1 |
| Goswami, S | 1 |
| Rienzi, N | 1 |
| Kaul, DK | 1 |
| Chen, B | 1 |
| Whitehurst, VE | 1 |
| Joseph, X | 1 |
| Vick, JA | 1 |
| Alleva, FR | 1 |
| Balazs, T | 2 |
| Schmidt, C | 1 |
| Schwendenwein, I | 1 |
| Wieselthaler, G | 1 |
| Roschal, K | 1 |
| Schima, H | 1 |
| Losert, U | 1 |
| Wolner, E | 1 |
| Stark, U | 1 |
| Stark, G | 1 |
| Kasper, K | 1 |
| Decrinis, M | 1 |
| Domanovits, H | 1 |
| Sterz, F | 1 |
| Belardinelli, L | 1 |
| Tritthart, HA | 1 |
| Gautam, CS | 1 |
| Sharma, PL | 1 |
| Pandhi, P | 1 |
| Gupta, B | 1 |
| Agarwala, A | 1 |
| Moy, JJ | 1 |
| Edward, DP | 1 |
| Yaman, O | 1 |
| Ozer, G | 1 |
| Soygür, T | 1 |
| Kutsal, O | 1 |
| Yaman, LS | 1 |
| Göŭş, O | 1 |
| Thomas, SH | 1 |
| Stone, CK | 1 |
| Koury, SI | 1 |
| al-Dohayan, AD | 1 |
| al-Tuwaijri, AS | 1 |
| Jäger, W | 1 |
| Idrizbegovic, E | 1 |
| Karlsson, KK | 1 |
| Alván, G | 1 |
| Köksoy, FN | 1 |
| Köse, H | 1 |
| Soybír, GR | 1 |
| Yalçin, O | 1 |
| Cokneşelí, B | 1 |
| Rosenthal, T | 1 |
| Erlich, Y | 1 |
| Rosenmann, E | 1 |
| Cohen, A | 1 |
| Popović, M | 1 |
| Caballero-Bleda, M | 1 |
| Popović, N | 1 |
| Bokonjić, D | 1 |
| Dobrić, S | 1 |
| Haraguchi, K | 1 |
| Ito, K | 1 |
| Kotaki, H | 1 |
| Sawada, Y | 1 |
| Iga, T | 1 |
| Adsan, H | 1 |
| Tulunay, M | 1 |
| Onaran, O | 1 |
| Dal Ponte, DB | 1 |
| Fogt, DL | 1 |
| Jacob, S | 1 |
| Henriksen, EJ | 1 |
| Bellamy, WT | 1 |
| Odeleye, A | 1 |
| Huizenga, E | 1 |
| Dalton, WS | 1 |
| Weinstein, RS | 1 |
| Grogan, TM | 1 |
| Griffin, KA | 1 |
| Picken, MM | 1 |
| Bakris, GL | 1 |
| Bidani, AK | 1 |
| Chen, YJ | 1 |
| Lee, SH | 1 |
| Hsieh, MH | 1 |
| Hsiao, CJ | 1 |
| Yu, WC | 1 |
| Chiou, CW | 1 |
| Chen, SA | 1 |
| Topçu, O | 1 |
| Akbay, C | 1 |
| Sayin, N | 1 |
| Korkmaz, C | 1 |
| Furuya, M | 1 |
| Yoshida, K | 1 |
| Sugiyama, A | 1 |
| Takehana, S | 1 |
| Kimura, R | 1 |
| Van Molle, W | 1 |
| Vanden Berghe, J | 1 |
| Brouckaert, P | 1 |
| Libert, C | 1 |
| Rafatro, H | 1 |
| Ramanitrahasimbola, D | 1 |
| Rasoanaivo, P | 1 |
| Ratsimamanga-Urverg, S | 1 |
| Rakoto-Ratsimamanga, A | 1 |
| Frappier, F | 1 |
| Meirelles Pereira, LM | 1 |
| Blaufeux, B | 1 |
| Hughes, S | 1 |
| Almond, GL | 1 |
| Homel, P | 1 |
| Ruha, AM | 1 |
| Curry, SC | 1 |
| Graeme, KA | 1 |
| Reagan, CG | 1 |
| Towbin, JA | 1 |
| Bowles, NE | 1 |
| Cohn, RD | 1 |
| Durbeej, M | 1 |
| Moore, SA | 1 |
| Coral-Vazquez, R | 1 |
| Prouty, S | 1 |
| Campbell, KP | 1 |
| Ruiz-Marcos, FM | 1 |
| Ortíz, MC | 1 |
| Fortepiani, LA | 1 |
| Nadal, FJ | 1 |
| Atucha, NM | 1 |
| García-Estañ, J | 1 |
| Duytschaever, MF | 1 |
| Garratt, CJ | 1 |
| Allessie, MA | 1 |
| Skoczyńska, A | 1 |
| Wróbel, J | 1 |
| Andrzejak, R | 1 |
| Tanaka, Y | 1 |
| Masuzawa, T | 1 |
| Saito, M | 1 |
| Yamada, T | 1 |
| Huang, P | 1 |
| Hawthorne, WJ | 1 |
| Peng, A | 1 |
| Angeli, GL | 1 |
| Medbury, HJ | 1 |
| Fletcher, JP | 1 |
| Sahin, M | 1 |
| Başar, MM | 1 |
| Bozdoğan, O | 1 |
| Atan, A | 1 |
| Petkova, SB | 1 |
| Rojkind, M | 1 |
| Dominguez-Rosales, JA | 1 |
| Hoffmann, E | 1 |
| Janko, S | 1 |
| Reithmann, C | 1 |
| Steinbeck, G | 1 |
| Hou, CR | 1 |
| Chung, KC | 1 |
| Chen, JT | 1 |
| Hong, CZ | 1 |
| Min, JY | 1 |
| Meissner, A | 1 |
| Morgan, JP | 1 |
| Lossnitzer, K | 1 |
| Konrad, A | 1 |
| Heine, HW | 1 |
| Ziegler, E | 1 |
| Stauch, M | 1 |
| Singh, BN | 1 |
| Smith, HJ | 1 |
| Norris, RM | 1 |
| Elharrar, V | 1 |
| Gaum, WE | 1 |
| Zipes, DP | 1 |
| Berdeaux, A | 1 |
| Coutte, R | 1 |
| Giudicelli, J | 1 |
| Boissier, J | 1 |
| Siden, R | 1 |
| Kadish, A | 1 |
| Flowers, W | 1 |
| Kutas, L | 1 |
| Bieneman, BK | 1 |
| DePietro, J | 1 |
| Jenkins, JP | 1 |
| Gallagher, KP | 1 |
| Levy, RJ | 1 |
| Aliev, MA | 1 |
| Lemeshenko, VA | 1 |
| Bekbolotova, AK | 1 |
| Ukimura, O | 1 |
| Kojima, M | 1 |
| Itoh, H | 1 |
| Hosoi, S | 1 |
| Watanabe, H | 1 |
| Yoshikawa, T | 1 |
| Akaishi, M | 1 |
| Ikeda, F | 1 |
| Handa, S | 1 |
| Nakamura, Y | 1 |
| Bailey, KR | 2 |
| Little, HJ | 1 |
| Powell, JS | 1 |
| Müller, RK | 1 |
| Rouge, M | 1 |
| Kuhn, H | 1 |
| Hefti, F | 1 |
| Baumgartner, HR | 1 |
| Fleischer, JE | 1 |
| Nakakimura, K | 1 |
| Drummond, JC | 1 |
| Scheller, MS | 1 |
| Zornow, MH | 1 |
| Grafe, MR | 1 |
| Shapiro, HM | 1 |
| Kishimoto, T | 1 |
| Tsujino, T | 1 |
| Nakatani, T | 1 |
| Kim, T | 1 |
| Ohyama, A | 1 |
| Yoshimura, R | 1 |
| Sakamoto, W | 1 |
| Maekawa, T | 1 |
| Kawashima, H | 1 |
| Kusunose, E | 1 |
| Poloński, L | 1 |
| Polońska, A | 1 |
| Tendera, M | 1 |
| Wodniecki, J | 1 |
| Krzywiecki, A | 1 |
| Shvilkin, AV | 1 |
| Afonskaia, NI | 1 |
| Sadretdinov, SM | 1 |
| Cherpachenko, NM | 1 |
| Levitskiĭ, DO | 1 |
| Ruda, MIa | 1 |
| Jolly, SR | 1 |
| Keaton, N | 1 |
| Movahed, A | 1 |
| Rose, GC | 1 |
| Reeves, WC | 1 |
| Videcoq, M | 1 |
| Ramsay, JG | 1 |
| Stone, JG | 1 |
| Foëx, P | 1 |
| Ryder, WA | 1 |
| Amagasa, M | 1 |
| Ogawa, A | 1 |
| Yoshimoto, T | 1 |
| von Planta, M | 1 |
| Weil, MH | 1 |
| Gazmuri, RJ | 1 |
| Ritz, MA | 1 |
| Rackow, EC | 1 |
| Handa, J | 1 |
| Shiino, A | 1 |
| Kidooka, M | 1 |
| Buja, LM | 2 |
| Clubb, FJ | 1 |
| Bilheimer, DW | 2 |
| Willerson, JT | 2 |
| Yamamoto, F | 1 |
| Manning, AS | 1 |
| Crome, R | 1 |
| Braimbridge, MV | 1 |
| Hearse, DJ | 2 |
| Bilezikian, JP | 1 |
| Matsumori, A | 1 |
| Tominaga, M | 1 |
| Kawai, C | 1 |
| Cox, E | 1 |
| Cools, V | 1 |
| Houvenaghel, A | 1 |
| Wauquier, A | 1 |
| Melis, W | 1 |
| Janssen, PA | 1 |
| Ueda, T | 1 |
| Yamamoto, YL | 1 |
| Diksic, M | 1 |
| Wagner, JA | 1 |
| Reynolds, IJ | 1 |
| Weisman, HF | 1 |
| Dudeck, P | 1 |
| Weisfeldt, ML | 1 |
| Snyder, SH | 1 |
| Hsueh, W | 1 |
| Gonzalez-Crussi, F | 1 |
| Arroyave, JL | 1 |
| Myers, AK | 1 |
| Forman, G | 1 |
| Torres Duarte, AP | 1 |
| Penhos, J | 1 |
| Ramwell, P | 1 |
| Zimmer, HG | 1 |
| Zierhut, W | 1 |
| Marschner, G | 1 |
| Aniukhovskiĭ, EP | 1 |
| Beloshapko, GG | 1 |
| Rozenshtraukh, LV | 1 |
| Curtis, MJ | 1 |
| Walker, MJ | 1 |
| Przyklenk, K | 1 |
| Golueke, PJ | 1 |
| Kahng, KU | 1 |
| Lipkowitz, GS | 1 |
| O'Neill, PA | 1 |
| Wait, RB | 1 |
| Akopov, SE | 1 |
| Sarkisian, SB | 1 |
| Gabrielian, ES | 1 |
| Woolley, JL | 1 |
| Barker, GR | 1 |
| Jacobsen, WK | 1 |
| Gingrich, GA | 1 |
| Stewart, SC | 1 |
| Briggs, BA | 1 |
| Martin, RD | 1 |
| Melashenko, RA | 1 |
| Harris, DC | 1 |
| Chan, L | 1 |
| Christie-Pope, BC | 1 |
| Palmer, GC | 1 |
| Parmley, WW | 3 |
| Jain, A | 1 |
| Homan, J | 1 |
| Symes, J | 1 |
| Jothy, S | 1 |
| Yunge, L | 1 |
| Huttner, I | 1 |
| Sniderman, A | 1 |
| Kingma, JG | 1 |
| Denniss, AR | 1 |
| Downey, JM | 1 |
| Yellon, DM | 1 |
| Ortega, MP | 1 |
| Sunkel, C | 1 |
| Priego, JG | 1 |
| Statkow, PR | 1 |
| Golikov, AP | 1 |
| Avilova, OA | 1 |
| Polumiskov, VIu | 1 |
| Berestov, AA | 1 |
| Konorev, EA | 1 |
| Johnson, GL | 1 |
| Ehrreich, SJ | 1 |
| el-Hage, AN | 1 |
| Todd, EL | 1 |
| Abernethy, DR | 1 |
| Cobb, FR | 1 |
| Murdock, RH | 1 |
| Greenfield, JC | 1 |
| Becker, LC | 1 |
| Bulkley, BH | 1 |
| Hutchins, GM | 1 |
| Schwartz, RP | 1 |
| Blumlein, S | 1 |
| Sievers, R | 2 |
| Wikman-Coffelt, J | 1 |
| Jasmin, G | 1 |
| Evans, RG | 1 |
| Val-Mejias, JE | 1 |
| Kulevich, J | 1 |
| Fischer, VW | 1 |
| Mueller, HS | 1 |
| Tilton, GD | 1 |
| Apprill, P | 1 |
| Ashton, J | 1 |
| McNatt, J | 1 |
| Kita, T | 1 |
| Tsuji, H | 1 |
| Zhang, XF | 1 |
| Alps, BJ | 1 |
| Calder, C | 1 |
| Wilson, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effects of High Altitude on 5' Adenosine Monophosphate-activated Protein Kinase (AMPK) Activation and Peroxisome Proliferator-activated Receptor Gamma (PPARγ) Regulation[NCT02391519] | 84 participants (Anticipated) | Observational | 2016-01-31 | Recruiting | |||
| Phase Ib/II Clinical Trial of Topical Verapamil Hydrochloride for Chronic Rhinosinusitis With Nasal Polyps[NCT03102190] | Phase 1 | 6 participants (Actual) | Interventional | 2017-06-05 | Terminated (stopped due to Phase II funding not available) | ||
| Randomized Double Blind Placebo Controlled Trial of Verapamil in Chronic Rhinosinusitis[NCT02454608] | 29 participants (Actual) | Interventional | 2015-05-31 | Terminated (stopped due to Evidence that the dose is insufficient.) | |||
| An Investigation Into the Effects of Intravenous Lipid Emulsion (ILE) on the Pharmacokinetic and Pharmacodynamic Properties of Metoprolol.[NCT02924454] | Phase 4 | 10 participants (Actual) | Interventional | 2016-09-30 | Completed | ||
| Molecular - Genetic Alterations in Adipose Tissue After Change in Therapy From ACE Inhibitors to AT1 Receptor Blockers in Patients With Essential Hypertension[NCT01444833] | 35 participants (Anticipated) | Interventional | 2008-10-31 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Dose Limiting Toxicity will be defined as a development of 2nd or 3rd degree heart block as measured by an EKG. (Phase Ib primary outcome) (NCT03102190)
Timeframe: 1-8 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Phase Ib | 0 |
(NCT02454608)
Timeframe: Mean change between baseline and week 8 measurements
| Intervention | mmHg (Mean) |
|---|---|
| Treatment | -0.6 |
| Control | 1 |
(NCT02454608)
Timeframe: Mean change between baseline and week 8 measurements.
| Intervention | beats per minute (Mean) |
|---|---|
| Treatment | -1.4 |
| Control | 4 |
Minimum Score: 0 Maximum Score: 12 Higher value represents worse outcome. (NCT02454608)
Timeframe: baseline to week 8
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Treatment | -1.3 |
| Control | -0.25 |
Minimum Score: 0 Maximum Score: 24 Higher value represents worse outcome. (NCT02454608)
Timeframe: Week 8
| Intervention | units on a scale (Mean) |
|---|---|
| Treatment | 12.5 |
| Control | 17.7 |
Minimum Score: 0 Maximum Score: 100 A higher score indicates a worse outcome. (NCT02454608)
Timeframe: baseline to week 8
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Treatment | -44.03 |
| Control | -6.07 |
Minimum Score: 0 Maximum Score: 110 A higher score indicates a worse outcome (NCT02454608)
Timeframe: baseline to week 8
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Treatment | -27.3 |
| Control | 0.4 |
(NCT02454608)
Timeframe: Mean change between baseline and week 8 measurements
| Intervention | mmHg (Mean) |
|---|---|
| Treatment | -4.5 |
| Control | -6.6 |
Minimum Score: 0 Maximum Score: 100 A higher score indicates a worse outcome. (NCT02454608)
Timeframe: baseline to week 56
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| Medicine Completers, baseline | Medicine Completers, week 56 | Surgical Completers, baseline | Surgical Completers, week 12 | |
| Open Label | 64.3 | 35.0 | 90.0 | 16.7 |
Minimum Score: 0 Maximum Score: 110 A higher score indicates a worse outcome (NCT02454608)
Timeframe: baseline to week 56
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| Medicine Completers, baseline | Medicine Completers, week 56 | Surgical Completers, baseline | Surgical Completers, week 12 | |
| Open Label | 31.8 | 24.14 | 72.00 | 8.00 |
14 reviews available for verapamil and Disease Models, Animal
| Article | Year |
|---|---|
Topics: Acetylcholine; Acinetobacter baumannii; Actinobacteria; Action Potentials; Adalimumab; Adaptation, P | 2019 |
Point of View: Electrophysiological Endpoints Differ When Comparing the Mode of Action of Highly Successful Anti-arrhythmic Drugs in the CAVB Dog Model With TdP.
Topics: Action Potentials; Aniline Compounds; Animals; Anti-Arrhythmia Agents; Atrioventricular Block; Chron | 2019 |
[Role of apoptosis in the kidney after reperfusion].
Topics: Animals; Apoptosis; Bepridil; Calcium Channel Blockers; Disease Models, Animal; Fendiline; Humans; K | 2008 |
Do calcium channel blockers have renal protective effects?
Topics: Aging; Animals; Calcium Channel Blockers; Clinical Trials as Topic; Cyclosporine; Diabetic Nephropat | 1994 |
Myocardial protection in the occlusion/reperfusion dog model: the role of ischemic necrosis vs reperfusion injury.
Topics: Animals; Coronary Vessels; Deferoxamine; Disease Models, Animal; Dogs; Free Radicals; Iron; Myocardi | 1995 |
[Mechanisms of initiation in atrial fibrillation].
Topics: Action Potentials; Algorithms; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Calcium Channel | 2002 |
The benzodiazepines: anxiolytic and withdrawal effects.
Topics: Animals; Anti-Anxiety Agents; Anxiety; Carbolines; Diazepam; Disease Models, Animal; Ethanol; Flumaz | 1991 |
Role of calcium channel blockers in protection against experimental renal injury.
Topics: Acute Kidney Injury; Animals; Calcium; Disease Models, Animal; Dogs; Glomerular Filtration Rate; Hum | 1991 |
[Ca antagonists in neurosurgical practice].
Topics: Animals; Anticonvulsants; Brain; Calcium Channel Blockers; Cerebral Infarction; Disease Models, Anim | 1990 |
Pathobiology of human familial hypercholesterolaemia and a related animal model, the Watanabe heritable hyperlipidaemic rabbit.
Topics: Animals; Cytoplasm; Disease Models, Animal; Dogs; Humans; Hyperlipidemia, Familial Combined; Hyperli | 1990 |
Effect of verapamil on postischemic "stunned" myocardium: importance of the timing of treatment.
Topics: Adenosine Triphosphate; Animals; Coronary Circulation; Coronary Disease; Disease Models, Animal; Dog | 1988 |
Calcium channel blockers and atherogenesis.
Topics: Animals; Aorta; Arteries; Arteriosclerosis; Calcium; Calcium Channel Blockers; Cholesterol, Dietary; | 1987 |
Effects of calcium-channel blockers on myocardial preservation during experimental acute myocardial infarction.
Topics: Animals; Calcium Channel Blockers; Collateral Circulation; Coronary Circulation; Coronary Disease; D | 1985 |
Modification of experimental atherosclerosis by calcium-channel blockers.
Topics: Animals; Aorta; Arteriosclerosis; Calcium; Calcium Channel Blockers; Child; Diet, Atherogenic; Dilti | 1985 |
2 trials available for verapamil and Disease Models, Animal
| Article | Year |
|---|---|
Basic and clinical research on the therapeutic effect of intervention in primary liver cancer by targeted intra-arterial verapamil infusion.
Topics: Adult; Aged; Alanine Transaminase; alpha-Fetoproteins; Animals; Antineoplastic Agents; Aspartate Ami | 2012 |
Pharmacological effects of aqueous-ethanolic extract of Hibiscus rosasinensis on volume and acidity of stimulated gastric secretion.
Topics: Animals; Anti-Ulcer Agents; Calcium Channel Blockers; Carbachol; Cimetidine; Disease Models, Animal; | 2011 |
258 other studies available for verapamil and Disease Models, Animal
| Article | Year |
|---|---|
A clinical drug library screen identifies astemizole as an antimalarial agent.
Topics: Animals; Antimalarials; Astemizole; Chloroquine; Disease Models, Animal; Dose-Response Relationship, | 2006 |
How well can the Caco-2/Madin-Darby canine kidney models predict effective human jejunal permeability?
Topics: Animals; Disease Models, Animal; Dogs; Humans; Jejunal Diseases; Kidney Diseases; Models, Biological | 2010 |
Neuroprotective efficacy of quinazoline type phosphodiesterase 7 inhibitors in cellular cultures and experimental stroke model.
Topics: Animals; Blood-Brain Barrier; Cells, Cultured; Cyclic Nucleotide Phosphodiesterases, Type 7; Disease | 2012 |
Synthesis of new N-benzylpiperidine derivatives as cholinesterase inhibitors with β-amyloid anti-aggregation properties and beneficial effects on memory in vivo.
Topics: Acetylcholinesterase; Alzheimer Disease; Amnesia; Amyloid beta-Peptides; Animals; Blood-Brain Barrie | 2015 |
Discovery of potent nitrotriazole-based antitrypanosomal agents: In vitro and in vivo evaluation.
Topics: Animals; Binding Sites; Cell Line; Chagas Disease; Disease Models, Animal; Leishmania donovani; Mice | 2015 |
Identification and Characterization of AES-135, a Hydroxamic Acid-Based HDAC Inhibitor That Prolongs Survival in an Orthotopic Mouse Model of Pancreatic Cancer.
Topics: Animals; Apoptosis; Benzamides; Cell Line, Tumor; Cell Proliferation; Coculture Techniques; Disease | 2019 |
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
Topics: Animals; Behavior, Animal; Cell-Free System; Dermatitis, Contact; Disease Models, Animal; Ganglia, S | 2019 |
Substituted benzothiophene and benzofuran derivatives as a novel class of bone morphogenetic Protein-2 upregulators: Synthesis, anti-osteoporosis efficacies in ovariectomized rats and a zebrafish model, and ADME properties.
Topics: Animals; Benzofurans; Bone Morphogenetic Protein 2; Caco-2 Cells; Disease Models, Animal; Dose-Respo | 2020 |
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Dr | 2020 |
Tetrahydroquinoline-Capped Histone Deacetylase 6 Inhibitor SW-101 Ameliorates Pathological Phenotypes in a Charcot-Marie-Tooth Type 2A Mouse Model.
Topics: Acetylation; Animals; Benzamides; Binding Sites; Charcot-Marie-Tooth Disease; Crystallography, X-Ray | 2021 |
Design, synthesis, and in vitro and in vivo characterization of new memantine analogs for Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Caenorhabditis elegans; Disease Models, Animal; Memantine; Mice; Recepto | 2022 |
Nitroimidazopyrazinones with Oral Activity against Tuberculosis and Chagas Disease in Mouse Models of Infection.
Topics: Animals; Chagas Disease; Disease Models, Animal; Mice; Mycobacterium tuberculosis; Nitroimidazoles; | 2022 |
Verapamil attenuates oxidative stress and inflammatory responses in cigarette smoke (CS)-induced murine models of acute lung injury and CSE-stimulated RAW 264.7 macrophages via inhibiting the NF-κB pathway.
Topics: Acute Lung Injury; Animals; Cigarette Smoking; Disease Models, Animal; Interleukin-6; Lipopolysaccha | 2022 |
The Combined Treatment of Curcumin with Verapamil Ameliorates the Cardiovascular Pathology in a Williams-Beuren Syndrome Mouse Model.
Topics: Animals; Aortic Stenosis, Supravalvular; Curcumin; Disease Models, Animal; Mice; Verapamil; Williams | 2023 |
Chronic Administration of Ion Channel Blockers Impact Microglia Morphology and Function in a Murine Model of Alzheimer's Disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Carbamazepine; Di | 2023 |
The therapeutic effect of verapamil in lipopolysaccharide-induced acute lung injury.
Topics: Acute Lung Injury; Animals; Cells, Cultured; Cytokines; Disease Models, Animal; Inflammation; Inflam | 2019 |
Evaluation of intestinal permeation enhancement with carboxymethyl chitosan-rhein polymeric micelles for oral delivery of paclitaxel.
Topics: Administration, Oral; Animals; Anthraquinones; Antineoplastic Agents, Phytogenic; ATP Binding Casset | 2020 |
Designing nanoparticles with improved tumor penetration: surface properties from the molecular architecture viewpoint.
Topics: Animals; Cell Line, Tumor; Cell Survival; Dendrimers; Disease Models, Animal; Drug Resistance, Neopl | 2019 |
Effect of Colloidal Aqueous Solution of Fullerene (C60) in the Presence of a P-Glycoprotein Inhibitor (Verapamil) on Spatial Memory and Hippocampal Expression of Sirtuin6, SELADIN1, and AQP1 Genes in a Rat Model of Alzheimer's Disease.
Topics: Alzheimer Disease; Animals; Aquaporin 1; ATP Binding Cassette Transporter, Subfamily B; Disease Mode | 2020 |
Acacetin suppresses the electrocardiographic and arrhythmic manifestations of the J wave syndromes.
Topics: Ajmaline; Animals; Brugada Syndrome; Disease Models, Animal; Dogs; Drug Evaluation, Preclinical; Ele | 2020 |
Design, synthesis and biological evaluation of novel pyxinol derivatives with anti-heart failure activity.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Cell Line; Disease Models, Animal; Drug Design; E | 2021 |
Verapamil Prevents Development of Cognitive Impairment in an Aged Mouse Model of Sporadic Alzheimer's Disease.
Topics: Aging; Alzheimer Disease; Animals; Brain; Calcium Channel Blockers; Cognitive Dysfunction; Disease M | 2021 |
Effects of Propranolol and Verapamil on Changes in TQ and ST Segment Potentials During Graded Coronary Flow Reduction in a Porcine Myocardial Ischemia Model.
Topics: Adrenergic beta-Antagonists; Animals; Calcium Channel Blockers; Disease Models, Animal; Electrocardi | 2017 |
Activity-Dependent Brain-Derived Neurotrophic Factor Release Is Required for the Rapid Antidepressant Actions of Scopolamine.
Topics: Animals; Antidepressive Agents; Brain; Brain-Derived Neurotrophic Factor; Calcium Channels, L-Type; | 2018 |
Comparative metabonomics of Wenxin Keli and Verapamil reveals differential roles of gluconeogenesis and fatty acid β-oxidation in myocardial injury protection.
Topics: Animals; Biomarkers; Cardiotonic Agents; Disease Models, Animal; Drugs, Chinese Herbal; Fatty Acids; | 2017 |
The Requirement of L-Type Voltage-Dependent Calcium Channel (L-VDCC) in the Rapid-Acting Antidepressant-Like Effects of Scopolamine in Mice.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Brain-Derived Neurotrophic Factor; Calcium Channel | 2018 |
Postnatal developmental changes in the sensitivity of L-type Ca
Topics: Animals; Bradycardia; Calcium Channel Blockers; Calcium Channels, L-Type; Diltiazem; Disease Models, | 2018 |
Nephroprotective effect of cilostazol and verapamil against thioacetamide-induced toxicity in rats may involve Nrf2/HO-1/NQO-1 signaling pathway.
Topics: Animals; Antioxidants; Cilostazol; Cytoprotection; Disease Models, Animal; Heme Oxygenase (Decyclizi | 2019 |
Topics: Administration, Oral; Animals; Blood Pressure; Disease Models, Animal; Drug Administration Schedule; | 2019 |
Enhancing the Engraftment of Human Induced Pluripotent Stem Cell-derived Cardiomyocytes via a Transient Inhibition of Rho Kinase Activity.
Topics: Amides; Animals; Cell Adhesion; Cell Adhesion Molecules; Cell Differentiation; Cells, Cultured; Dise | 2019 |
Nephroprotective effect of calcium channel blockers against toxicity of lead exposure in mice.
Topics: Animals; Apoptosis; Blood Urea Nitrogen; Body Weight; Calcium Channel Blockers; Creatinine; Cytoprot | 2013 |
Multimodal imaging in rats reveals impaired neurovascular coupling in sustained hypertension.
Topics: Animals; Antihypertensive Agents; Calcium Channel Blockers; Cerebrovascular Circulation; Disease Mod | 2013 |
Altered brain uptake of therapeutics in a triple transgenic mouse model of Alzheimer's disease.
Topics: Alzheimer Disease; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Tran | 2013 |
Contractile abnormalities and altered drug response in engineered heart tissue from Mybpc3-targeted knock-in mice.
Topics: Adrenergic beta-Agonists; Animals; Calcium; Calcium Channel Blockers; Cardiomyopathy, Hypertrophic; | 2013 |
Anti-arrhythmic effect of verapamil is accompanied by preservation of cx43 protein in rat heart.
Topics: 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl e | 2013 |
Curine inhibits eosinophil activation and airway hyper-responsiveness in a mouse model of allergic asthma.
Topics: Administration, Oral; Animals; Anti-Asthmatic Agents; Asthma; Bronchial Hyperreactivity; Calcium; Di | 2013 |
Physiology and analysis of the electrocardiographic T wave in mice.
Topics: Adrenergic beta-Agonists; Animals; Calcium Channel Blockers; Chronic Disease; Disease Models, Animal | 2013 |
Verapamil augments the neuroprotectant action of berberine in rat model of transient global cerebral ischemia.
Topics: Acetylcholinesterase; Animals; Behavior, Animal; Berberine; Brain; Disease Models, Animal; Glutathio | 2013 |
Protective effect of selected calcium channel blockers and prednisolone, a phospholipase-A2 inhibitor, against gentamicin and carbon tetrachloride-induced nephrotoxicity.
Topics: Animals; Antioxidants; Biomarkers; Calcium Channel Blockers; Carbon Tetrachloride; Cytoprotection; D | 2014 |
P-glycoprotein alters blood-brain barrier penetration of antiepileptic drugs in rats with medically intractable epilepsy.
Topics: Animals; Anticonvulsants; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blood-Brain Barri | 2013 |
Verapamil protects against cartilage degradation in osteoarthritis by inhibiting Wnt/β-catenin signaling.
Topics: Animals; beta Catenin; Biomarkers; Calcium Channel Blockers; Cartilage; Chondrocytes; Chondrogenesis | 2014 |
P-glycoprotein activity in the blood-brain barrier is affected by virus-induced neuroinflammation and antipsychotic treatment.
Topics: Animals; Antipsychotic Agents; ATP Binding Cassette Transporter, Subfamily B; Blood-Brain Barrier; B | 2014 |
Pharmacoproteomics-based reconstruction of in vivo P-glycoprotein function at blood-brain barrier and brain distribution of substrate verapamil in pentylenetetrazole-kindled epilepsy, spontaneous epilepsy, and phenytoin treatment models.
Topics: Animals; Anticonvulsants; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blood-Brain Barri | 2014 |
Verapamil increases the bactericidal activity of bedaquiline against Mycobacterium tuberculosis in a mouse model.
Topics: Animals; Antitubercular Agents; Calcium Channel Blockers; Diarylquinolines; Disease Models, Animal; | 2015 |
Comparison of combination therapy (steroid, calcium channel blocker, and interferon) with steroid monotherapy for treating human hypertrophic scars in an animal model.
Topics: Adult; Animals; Calcium Channel Blockers; Cicatrix, Hypertrophic; Disease Models, Animal; Drug Thera | 2015 |
Therapeutic effect of Qingyi decoction in severe acute pancreatitis-induced intestinal barrier injury.
Topics: Acute Disease; Amine Oxidase (Copper-Containing); Amylases; Animals; Anti-Inflammatory Agents; Apopt | 2015 |
Defective parasympathetic innervation is associated with airway branching abnormalities in experimental CDH.
Topics: Animals; Calcium Channel Blockers; Carbachol; Cardiotonic Agents; Disease Models, Animal; Embryo, Ma | 2015 |
Reversal of P-glycoprotein overexpression by Ginkgo biloba extract in the brains of pentylenetetrazole-kindled and phenytoin-treated mice.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Brain; Caspase 3; Disease Models, | 2015 |
Multidrug resistance protein 1 reduces the aggregation of mutant huntingtin in neuronal cells derived from the Huntington's disease R6/2 model.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blotting, Western; Cells, Cultured | 2015 |
Topical Application of a Silicone Gel Sheet with Verapamil Microparticles in a Rabbit Model of Hypertrophic Scar.
Topics: Administration, Topical; Animals; Cell-Derived Microparticles; Cicatrix, Hypertrophic; Disease Model | 2016 |
Comparison of Effects of Separate and Combined Sugammadex and Lipid Emulsion Administration on Hemodynamic Parameters and Survival in a Rat Model of Verapamil Toxicity.
Topics: Animals; Blood Pressure; Disease Models, Animal; Emulsions; gamma-Cyclodextrins; Heart Rate; Hemodyn | 2016 |
Antihypertensive activity of 80% methanol seed extract of Calpurnia aurea (Ait.) Benth. subsp. aurea (Fabaceae) is mediated through calcium antagonism induced vasodilation.
Topics: Animals; Antihypertensive Agents; Aorta, Thoracic; Blood Pressure; Calcium Channel Blockers; Disease | 2016 |
The combination of Everolimus with Verapamil reduces ovarian weight and vascular permeability on ovarian hyperstimulation syndrome: a preclinical experimental randomized controlled study.
Topics: Animals; Capillary Permeability; Cytochrome P-450 CYP3A Inhibitors; Disease Models, Animal; Everolim | 2016 |
Verapamil, a Calcium-Channel Blocker, Improves the Wound Healing Process in Rats with Excisional Full-Thickness Skin Wounds Based on Stereological Parameters.
Topics: Administration, Topical; Animals; Biopsy, Needle; Calcium Channel Blockers; Disease Models, Animal; | 2016 |
Intracellular renin increases the inward calcium current in smooth muscle cells of mesenteric artery of SHR. Implications for hypertension and vascular remodeling.
Topics: Amides; Angiotensin II; Animals; Calcium; Calcium Signaling; Disease Models, Animal; Fumarates; Huma | 2016 |
A Comparison of Gene Expression of Decorin and MMP13 in Hypertrophic Scars Treated With Calcium Channel Blocker, Steroid, and Interferon: A Human-Scar-Carrying Animal Model Study.
Topics: Adolescent; Adult; Animals; Burns; Calcium Channel Blockers; Child; Child, Preschool; Cicatrix; Cica | 2017 |
[Characteristics of pharmacological and toxic effects of verapamil during cardiac arrhythmia in thyrotoxic and hypothyroid rats].
Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Disease Models, Animal; Dose-Response Relatio | 2008 |
Determining the optimal dose of intravenous fat emulsion for the treatment of severe verapamil toxicity in a rodent model.
Topics: Acid-Base Equilibrium; Animals; Blood Pressure; Calcium Channel Blockers; Disease Models, Animal; Do | 2008 |
Diltiazem and verapamil protect dystrophin-deficient muscle fibers of MDX mice from degeneration: a potential role in calcium buffering and sarcolemmal stability.
Topics: Animals; Calcium; Calcium Channel Blockers; Calsequestrin; Creatine Kinase; Diltiazem; Disease Model | 2009 |
Early termination of spiral wave reentry by combined blockade of Na+ and L-type Ca2+ currents in a perfused two-dimensional epicardial layer of rabbit ventricular myocardium.
Topics: Animals; Calcium Channel Blockers; Calcium Channels, L-Type; Disease Models, Animal; Electrophysiolo | 2009 |
Mapping ventricular fibrillation: a simplified experimental model leads to a complicated result.
Topics: Animals; Calcium Channel Blockers; Calcium Channels, L-Type; Disease Models, Animal; Electrophysiolo | 2009 |
Letter regarding levosimendan in a rat model of severe verapamil poisoning.
Topics: Animals; Antidotes; Cardiotonic Agents; Cardiovascular Agents; Disease Models, Animal; Drug Overdose | 2009 |
Differential contractile impairment of fast- and slow-twitch skeletal muscles in a rat model of doxorubicin-induced congestive heart failure.
Topics: Action Potentials; Animals; Caffeine; Disease Models, Animal; Doxorubicin; Heart Failure; Male; Memb | 2009 |
The influence of P-glycoprotein expression and its inhibitors on the distribution of doxorubicin in breast tumors.
Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blood Vesse | 2009 |
In vivo and ex vivo evaluation of L-type calcium channel blockers on acid beta-glucosidase in Gaucher disease mouse models.
Topics: Animals; Calcium Channel Blockers; Calcium Channels, L-Type; Diltiazem; Disease Models, Animal; Fibr | 2009 |
Effects of diammonium glycyrrhizinate on the pharmacokinetics of aconitine in rats and the potential mechanism.
Topics: Aconitine; Administration, Oral; Animals; Biological Transport; Cyclosporine; Disease Models, Animal | 2009 |
Effect of levosimendan in experimental verapamil-induced myocardial depression.
Topics: Animals; Anti-Arrhythmia Agents; Calcium Channel Blockers; Disease Models, Animal; Heart Arrest; Hyd | 2010 |
Effects of sarcolemmal Ca(2+) entry, ryanodine function, and kinase inhibitors on a rabbit model of heart failure.
Topics: Animals; Anti-Arrhythmia Agents; Benzylamines; Disease Models, Animal; Heart Failure; Isoquinolines; | 2010 |
Effect of cyclodextrin infusion in a rat model of verapamil toxicity.
Topics: Animals; Apnea; beta-Cyclodextrins; Disease Models, Animal; Heart Arrest; Male; Osmolar Concentratio | 2011 |
Prevention of ventricular arrhythmia and calcium dysregulation in a catecholaminergic polymorphic ventricular tachycardia mouse model carrying calsequestrin-2 mutation.
Topics: Adrenergic beta-Antagonists; Animals; Anti-Arrhythmia Agents; Calcium Channel Blockers; Calcium Sign | 2011 |
Role of KATP and L-type Ca2+ channel activities in regulation of ovine uterine vascular contractility: effect of pregnancy and chronic hypoxia.
Topics: Adenosine Triphosphate; Altitude; Animals; Arteries; Calcium Channels, L-Type; Disease Models, Anima | 2010 |
Drug-disease interaction: reduced verapamil response in isoproterenol-induced myocardial injury in rats.
Topics: Animals; Blotting, Western; Calcium Channel Blockers; Calcium Channels, L-Type; Disease Models, Anim | 2010 |
The effect of combined steroid and calcium channel blocker injection on human hypertrophic scars in animal model: a new strategy for the treatment of hypertrophic scars.
Topics: Animals; Burns; Calcium Channel Blockers; Cell Proliferation; Cicatrix, Hypertrophic; Decorin; Disea | 2010 |
T-type calcium channel as a portal of iron uptake into cardiomyocytes of beta-thalassemic mice.
Topics: Animals; beta-Thalassemia; Calcium Channels, T-Type; Cell Survival; Cells, Cultured; Deferoxamine; D | 2011 |
Attenuation of proinflammatory cytokines and apoptotic process by verapamil and diltiazem against quinolinic acid induced Huntington like alterations in rats.
Topics: Analysis of Variance; Animals; Apoptosis; Body Weight; Calcium Channel Blockers; Catalase; Cytokines | 2011 |
Interdependence of cardiac iron and calcium in a murine model of iron overload.
Topics: Animals; Calcitriol; Calcium; Calcium Channel Agonists; Calcium Channel Blockers; Calcium Channels, | 2011 |
Increased expression of P-glycoprotein is associated with doxorubicin chemoresistance in the metastatic 4T1 breast cancer model.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Cell Line, T | 2011 |
Drug tolerance in replicating mycobacteria mediated by a macrophage-induced efflux mechanism.
Topics: Animals; Antitubercular Agents; Bacterial Proteins; Disease Models, Animal; Drug Tolerance; Granulom | 2011 |
Pharmacokinetics of verapamil in diabetic rats induced by combination of high-fat diet and streptozotocin injection.
Topics: Animals; Anti-Arrhythmia Agents; Cytochrome P-450 CYP3A; Diabetes Mellitus, Experimental; Diet; Diet | 2011 |
Rifampicin reduces susceptibility to ofloxacin in rifampicin-resistant Mycobacterium tuberculosis through efflux.
Topics: Adrenergic Uptake Inhibitors; Animals; Anti-Bacterial Agents; Antibiotics, Antitubercular; Bacterial | 2011 |
Hyperoxaluria-induced tubular ischemia: the effects of verapamil and vitamin E on apoptotic changes with an emphasis on renal papilla in rat model.
Topics: Animals; Apoptosis; Crystallization; Disease Models, Animal; Hyperoxaluria; In Situ Nick-End Labelin | 2012 |
Effects of high frequency electrical stimulation and R-verapamil on seizure susceptibility and glutamate and GABA release in a model of phenytoin-resistant seizures.
Topics: Animals; Disease Models, Animal; Disease Susceptibility; Drug Resistance; Electric Stimulation; Extr | 2011 |
A novel positron emission tomography imaging protocol identifies seizure-induced regional overactivity of P-glycoprotein at the blood-brain barrier.
Topics: Analysis of Variance; Animals; Area Under Curve; ATP Binding Cassette Transporter, Subfamily B, Memb | 2011 |
The effect of verapamil on in vitro susceptibility of promastigote and amastigote stages of Leishmania tropica to meglumine antimoniate.
Topics: Animals; Antiprotozoal Agents; Calcium Channel Blockers; Colorimetry; Disease Models, Animal; Drug S | 2012 |
L-type calcium channel mediates anticonvulsant effect of cannabinoids in acute and chronic murine models of seizure.
Topics: Acute Disease; Animals; Anticonvulsants; Benzamides; Benzoxazines; Calcium Channels, L-Type; Cannabi | 2012 |
In vivo imaging of human breast cancer mouse model with high level expression of calcium sensing receptor at 3T.
Topics: Animals; Breast Neoplasms; Cell Line, Tumor; Chlorides; Contrast Media; Disease Models, Animal; Fema | 2012 |
A comparative small-animal PET evaluation of [11C]tariquidar, [11C]elacridar and (R)-[11C]verapamil for detection of P-glycoprotein-expressing murine breast cancer.
Topics: Acridines; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; B | 2012 |
L-carnitine increases survival in a murine model of severe verapamil toxicity.
Topics: Animals; Blood Pressure; Calcium Channel Blockers; Carnitine; Disease Models, Animal; Infusions, Int | 2011 |
Effect of verapamil on bronchial goblet cells of asthma: an experimental study on sensitized animals.
Topics: Animals; Asthma; Bronchi; Bronchoalveolar Lavage Fluid; Calcium Channel Blockers; Disease Models, An | 2012 |
Effect of verapamil on bronchial goblet cells of asthma: an experimental study on sensitized animals.
Topics: Animals; Asthma; Bronchi; Bronchoalveolar Lavage Fluid; Calcium Channel Blockers; Disease Models, An | 2012 |
Effect of verapamil on bronchial goblet cells of asthma: an experimental study on sensitized animals.
Topics: Animals; Asthma; Bronchi; Bronchoalveolar Lavage Fluid; Calcium Channel Blockers; Disease Models, An | 2012 |
Effect of verapamil on bronchial goblet cells of asthma: an experimental study on sensitized animals.
Topics: Animals; Asthma; Bronchi; Bronchoalveolar Lavage Fluid; Calcium Channel Blockers; Disease Models, An | 2012 |
Verapamil as an antiarrhythmic agent in congestive heart failure: hopping from rabbit to human?
Topics: Animals; Anti-Arrhythmia Agents; Disease Models, Animal; Heart Failure; Humans; Rabbits; Verapamil | 2012 |
Calcium channel blockers reduce the effects of cigarette smoking on peripheral nerve ischemia/reperfusion injury.
Topics: Animals; Calcium Channel Blockers; Cotinine; Disease Models, Animal; Male; Nifedipine; Rats; Rats, W | 2013 |
T-type calcium channel blockade improves survival and cardiovascular function in thalassemic mice.
Topics: Animals; Azoles; Base Sequence; beta-Thalassemia; Calcium Channel Blockers; Calcium Channels, L-Type | 2012 |
Anti-psychotic and sedative effect of calcium channel blockers in mice.
Topics: Amphetamine; Animals; Antipsychotic Agents; Calcium Channel Blockers; Catalepsy; Disease Models, Ani | 2010 |
Suppression of intestinal polyp development in Apc(Min/+) mice through inhibition of P-glycoprotein using verapamil.
Topics: Adenomatous Polyposis Coli; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Diseas | 2013 |
Involvement of the endogenous hydrogen sulfide/Ca(v) 3.2 T-type Ca2+ channel pathway in cystitis-related bladder pain in mice.
Topics: Acetanilides; Animals; Benzimidazoles; Calcium Channel Blockers; Calcium Channels, T-Type; Cyclophos | 2012 |
Ferric iron uptake into cardiomyocytes of β-thalassemic mice is not through calcium channels.
Topics: Animals; Azoles; beta-Thalassemia; Calcium Channel Blockers; Calcium Channels; Calcium Channels, L-T | 2013 |
A comparative study of the efficacy of intralesional verapamil versus normal saline injection in a novel Peyronie disease animal model: assessment of immunohistopathological changes and erectile function outcome.
Topics: Animals; Disease Models, Animal; Immunohistochemistry; Injections, Intralesional; Male; Penile Erect | 2013 |
Influences of "spasmolytic powder" on pgp expression of Coriaria Lactone-kindling drug-resistant epileptic rat model.
Topics: Animals; Anticonvulsants; Arthropods; ATP Binding Cassette Transporter, Subfamily B, Member 1; Disea | 2013 |
Human cardiotoxic drugs delivered by soaking and microinjection induce cardiovascular toxicity in zebrafish.
Topics: Abnormalities, Drug-Induced; Animals; Aspirin; Cardiotoxins; Clomipramine; Cyclophosphamide; Disease | 2014 |
The relationship of clinical QT prolongation to outcome in the conscious dog using a beat-to-beat QT-RR interval assessment.
Topics: Animals; Anti-Arrhythmia Agents; Butylamines; Cisapride; Disease Models, Animal; Dogs; Female; Heart | 2002 |
Influence of propranolol, enalaprilat, verapamil, and caffeine on adenosine A(2A)-receptor-mediated coronary vasodilation.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Caffeine; Calcium Ch | 2002 |
Disparate effects of angiotensin II antagonists and calcium channel blockers on albuminuria in experimental diabetes and hypertension: potential role of nephrin.
Topics: Albuminuria; Amlodipine; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Blood P | 2003 |
[Effect of long term administration of finoptin on the morphofunctional state of working cells of the intact myocardium in modeling of chronic coronary insufficiency].
Topics: Animals; Calcium; Calcium Channel Blockers; Chronic Disease; Disease Models, Animal; Drug Evaluation | 2002 |
Low urinary kallikrein rats: different sensitivity of verapamil on hypertensive response to central acute cadmium administration.
Topics: Acetates; Animals; Blood Pressure; Cadmium; Calcium Channel Blockers; Disease Models, Animal; Dose-R | 2003 |
The effects of alpha - tocopherol and verapamil on mucosal functions after gut ischemia / reperfusion.
Topics: alpha-Tocopherol; Analysis of Variance; Animals; Disease Models, Animal; Dogs; Hypertonic Solutions; | 2003 |
Verapamil suppresses the inhomogeneity of electrical remodeling in a canine long-term rapid atrial stimulation model.
Topics: Analysis of Variance; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Pacing, Artifici | 2003 |
Endothelin-1 promotes Ca2+ antagonist-insensitive coronary smooth muscle contraction via activation of epsilon-protein kinase C.
Topics: Animals; Calcium; Calcium Channel Blockers; Coronary Vasospasm; Coronary Vessels; Diltiazem; Disease | 2004 |
Secondary coronary artery vasospasm promotes cardiomyopathy progression.
Topics: Animals; Calcium Channel Blockers; Cardiomyopathies; Coronary Vasospasm; Cytoskeletal Proteins; Dise | 2004 |
Effects of early and late verapamil administration on the development of cardiomyopathy in experimental chronic Trypanosoma cruzi (Brazil strain) infection.
Topics: Animals; Anti-Arrhythmia Agents; Cardiomyopathy, Dilated; Chagas Cardiomyopathy; Chagas Disease; Dis | 2004 |
Dose-dependent hemodynamic effect of digoxin therapy in severe verapamil toxicity.
Topics: Animals; Antidotes; Blood Pressure; Calcium Channel Blockers; Calcium Chloride; Digoxin; Disease Mod | 2004 |
Effects of adenosine and verapamil on anatomic no-reflow in a rabbit model of coronary artery occlusion and reperfusion.
Topics: Adenosine; Animals; Blood Pressure; Coronary Disease; Coronary Vasospasm; Disease Models, Animal; Ma | 2004 |
Effects of quercetin treatment on vascular function in deoxycorticosterone acetate-salt hypertensive rats. Comparative study with verapamil.
Topics: Animals; Antihypertensive Agents; Aorta; Blood Pressure; Desoxycorticosterone; Disease Models, Anima | 2004 |
Aortic wall remodeling in rats with nitric oxide deficiency treated by enalapril or verapamil.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Aorta, Thoracic; Blood Pressure; Calcium Channel | 2004 |
Limitation of apoptotic changes in renal tubular cell injury induced by hyperoxaluria.
Topics: Allopurinol; Animals; Apoptosis; Cells, Cultured; Disease Models, Animal; Hyperoxaluria; In Situ Nic | 2004 |
The influence of the calcium channel blocker verapamil on experimental glaucoma.
Topics: Animals; Calcium Channel Blockers; Disease Models, Animal; Epinephrine; Glaucoma; Intraocular Pressu | 2004 |
Myocardial infarction non-invasively induced in rabbits by administering isoproterenol and vasopressin: protective effects exerted by verapamil.
Topics: Animals; Blood Pressure; Calcium Channel Blockers; Disease Models, Animal; Electrocardiography; Hear | 2004 |
Use of vasopressin in a canine model of severe verapamil poisoning: a preliminary descriptive study.
Topics: Animals; Arginine Vasopressin; Blood Pressure; Calcium Channel Blockers; Disease Models, Animal; Dog | 2004 |
Effect of early phase adjuvant arthritis on hepatic P450 enzymes and pharmacokinetics of verapamil: an alternative approach to the use of an animal model of inflammation for pharmacokinetic studies.
Topics: Administration, Oral; Animals; Arthritis, Experimental; Blood Proteins; Cytochrome P-450 Enzyme Syst | 2005 |
Direct determination of verapamil in rat plasma by coupled column microbore-HPLC method.
Topics: Animals; Biological Availability; Calibration; Chromatography, High Pressure Liquid; Disease Models, | 2005 |
Chemosensitizing action of cepharanthine against drug-resistant human malaria, Plasmodium falciparum.
Topics: Alkaloids; Animals; Benzylisoquinolines; Chloroquine; Disease Models, Animal; Dose-Response Relation | 2005 |
Pharmacokinetics of verapamil and its major metabolite, norverapamil from oral administration of verapamil in rabbits with hepatic failure induced by carbon tetrachloride.
Topics: Administration, Oral; Animals; Biological Availability; Calcium Channel Blockers; Carbon Tetrachlori | 2005 |
Restoration of cerebral vasoreactivity by an L-type calcium channel blocker following fluid percussion brain injury.
Topics: Animals; Antipyrine; Blood Pressure; Brain Injuries; Calcium; Calcium Channel Blockers; Calcium Chan | 2005 |
Excessive activation of cyclic nucleotide-gated channels contributes to neuronal degeneration of photoreceptors.
Topics: 1-Methyl-3-isobutylxanthine; Animals; Animals, Newborn; Blotting, Western; Cadmium Chloride; Calcium | 2005 |
The comparative effects of calcium channel blockers in an experimental colitis model in rats.
Topics: Animals; Calcium Channel Blockers; Colitis; Diltiazem; Disease Models, Animal; Drug Administration S | 2004 |
Intralipid prolongs survival in a rat model of verapamil toxicity.
Topics: Animals; Calcium Channel Blockers; Confounding Factors, Epidemiologic; Disease Models, Animal; Dose- | 2006 |
Over-expression of Kv1.5 in rat cardiomyocytes extremely shortens the duration of the action potential and causes rapid excitation.
Topics: Action Potentials; Adenoviridae; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cells, Cultu | 2006 |
Effects of verapamil and nifedipine on different parameters in lipopolysaccharide-induced septic shock.
Topics: Animals; Calcium Channel Blockers; Carotid Arteries; Catalase; Disease Models, Animal; Interleukin-1 | 2006 |
Transport, metabolism, and in vivo population pharmacokinetics of the chloro benztropine analogs, a class of compounds extensively evaluated in animal models of drug abuse.
Topics: Animals; Benztropine; Biological Transport; Caco-2 Cells; Cell Line; Cocaine-Related Disorders; Cyto | 2007 |
Protective effect of verapamil on multiple hepatotoxic factors-induced liver fibrosis in rats.
Topics: Actins; Alanine Transaminase; Animals; Carbon Tetrachloride; Collagen; Dietary Fats; Disease Models, | 2007 |
Does chemical sympathectomy alter the ontogeny of gubernacular migration in vivo?
Topics: Analysis of Variance; Animals; Animals, Newborn; Biopsy, Needle; Cryptorchidism; Disease Models, Ani | 2007 |
Changes in T-type calcium channel and its subtypes in overactive detrusor of the rats with partial bladder outflow obstruction.
Topics: Action Potentials; Animals; Calcium Channels, T-Type; Disease Models, Animal; DNA Primers; Male; Mus | 2007 |
Hemodynamic effects of intralipid after verapamil intoxication may be due to a direct effect of fatty acids on myocardial calcium channels.
Topics: Animals; Calcium Channels; Disease Models, Animal; Dogs; Drug-Related Side Effects and Adverse React | 2007 |
Antimuscarinic drug inhibits detrusor overactivity induced by topical application of prostaglandin E2 to the urethra with a decrease in urethral pressure.
Topics: Administration, Intravesical; Administration, Topical; Adrenergic alpha-Antagonists; Animals; Atropi | 2007 |
Treatment of experimental verapamil poisoning with levosimendan utilizing a rodent model of drug toxicity.
Topics: Animals; Antidotes; Blood Pressure; Calcium Chloride; Cardiac Output; Disease Models, Animal; Heart | 2008 |
Vasopressin treatment of verapamil toxicity in the porcine model.
Topics: Animals; Antidotes; Blood Pressure; Cardiac Output; Disease Models, Animal; Heart Rate; Longevity; M | 2005 |
Effect of calcium antagonists in experimental asthma.
Topics: Anaphylaxis; Animals; Asthma; Calcium Channel Blockers; Depression, Chemical; Disease Models, Animal | 1982 |
Barium-treated mammalian skeletal muscle: similarities to hypokalaemic periodic paralysis.
Topics: Action Potentials; Animals; Barium; Disease Models, Animal; Hypokalemia; In Vitro Techniques; Ion Ch | 1983 |
[Evaluation of the efficacy of various hypotensive drugs in broad-breasted white turkeys as an experimental model of arterial hypertension with high catecholamine levels].
Topics: Animals; Antihypertensive Agents; Captopril; Catecholamines; Disease Models, Animal; Furosemide; Hyp | 1983 |
Protective effect of intrarenal calcium membrane blockers before or after renal ischemia. Functional, morphological, and mitochondrial studies.
Topics: Acute Kidney Injury; Animals; Calcium; Calcium Channel Blockers; Cytoplasm; Disease Models, Animal; | 1984 |
Verapamil in two reperfusion models of myocardial infarction. Temporary protection of severely ischemic myocardium without limitation of ultimate infarct size.
Topics: Animals; Collateral Circulation; Coronary Circulation; Coronary Disease; Disease Models, Animal; Dog | 1984 |
Evaluation of cardiac anoxia and ischemia models in the rat using calcium antagonists.
Topics: Adenine Nucleotides; Animals; Calcium Channel Blockers; Chromatography, High Pressure Liquid; Corona | 1984 |
In vivo effects of three calcium blockers on chickens with inherited muscular dystrophy.
Topics: Animals; Benzazepines; Calcium; Chickens; Creatine Kinase; Diltiazem; Disease Models, Animal; Female | 1984 |
[Pharmacologic evaluation of electrical processes in the myocardium].
Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Disease Models, Animal; Dogs; Drug Evaluation | 1982 |
Comparison of the antithrombotic action of calcium antagonist drugs with dipyridamole in dogs.
Topics: Animals; Blood Platelets; Calcium Channel Blockers; Dipyridamole; Disease Models, Animal; Dogs; Fibr | 1983 |
Autoradiographic method for measuring the ischemic myocardium at risk: effects of verapamil on infarct size aftr experimental coronary artery occlusion.
Topics: Albumins; Animals; Autoradiography; Coronary Disease; Disease Models, Animal; Dogs; Myocardial Infar | 1980 |
[Myocardial disease caused by adriamycin. Experimental animal models and possible pharmacologic prevention].
Topics: Animals; Cardiomyopathies; Carnitine; Disease Models, Animal; Doxorubicin; Mice; Rabbits; Rats; Razo | 1982 |
Influence of the extent of the zone at risk on the effectiveness of drugs in reducing infarct size.
Topics: Animals; Autoradiography; Calcium Channel Blockers; Collateral Circulation; Coronary Circulation; Di | 1982 |
[Immediate and intermediate effects of verapamil administration in rats with experimental renal hypertension].
Topics: Animals; Blood Pressure; Disease Models, Animal; Hemodynamics; Hypertension, Renal; Male; Rats; Rats | 1982 |
A new in vivo model of arterial thrombosis: the effect of administration of ticlopidine and verapamil in dogs.
Topics: Administration, Oral; Animals; Disease Models, Animal; Dogs; Drug Evaluation, Preclinical; Femoral A | 1982 |
[Effects of verapamil on arterial blood pressure and heart rate in awake animals with neurogenic and renal hypertension].
Topics: Animals; Blood Pressure; Disease Models, Animal; Heart Rate; Hypertension; Hypertension, Renal; Infu | 1982 |
[Coronary reperfusion in the rat. Protective effects of verapamil].
Topics: Animals; Arrhythmias, Cardiac; Coronary Vessels; Disease Models, Animal; Male; Perfusion; Rats; Vera | 1980 |
[Experimental arrhythmic models in mice and the factors affecting them (author's transl)].
Topics: Aconitine; Animals; Arrhythmias, Cardiac; Calcium; Disease Models, Animal; Female; Male; Manganese; | 1981 |
Assessment of pharmacological treatment of myocardial infarction by phosphorus-31 NMR with surface coils.
Topics: Animals; Chlorpromazine; Coronary Circulation; Disease Models, Animal; Magnetic Resonance Spectrosco | 1981 |
Actions of verapamil on Purkinje fibers from normal and infarcted heart tissues.
Topics: Animals; Cell Membrane Permeability; Disease Models, Animal; Dogs; Female; Heart Conduction System; | 1981 |
Antiarrhythmic effects of bisaramil on triggered arrhythmias produced by intracoronary injection of digitalis and adrenaline in the dog.
Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Bridged Bicyclo Compounds, Heterocyclic; Chlo | 1995 |
Effect of (+/-)-verapamil and hydralazine on stress- and chemically-induced gastric ulcers in rats.
Topics: Animals; Disease Models, Animal; Ethanol; Gastric Acid; Gastric Mucins; Hydralazine; Indomethacin; M | 1994 |
Studies in phlebitis. VII: In vitro and in vivo evaluation of pH-solubilized levemopamil.
Topics: Animals; Buffers; Calcium Channel Blockers; Disease Models, Animal; Hydrogen-Ion Concentration; In V | 1995 |
Antifibrillary action of class I-IV antiarrhythmic agents in the model of ventricular fibrillation threshold of anesthetized guinea pigs.
Topics: Adrenergic beta-Antagonists; Animals; Anti-Arrhythmia Agents; Atenolol; Benzopyrans; Chromans; Disea | 1995 |
Structure and function of the rat basilar artery during chronic nitric oxide synthase inhibition.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Arginine; Basilar Artery | 1995 |
Retinal artery occlusion in rabbit eyes using human atheroma.
Topics: Animals; Arteriosclerosis; Carotid Artery, Common; Catheterization, Peripheral; Cholesterol; Disease | 1995 |
Digoxin-induced ventricular arrhythmias in the guinea pig heart in vivo: evidence for a role of endogenous catecholamines in the genesis of delayed afterdepolarizations and triggered activity.
Topics: Adenosine; Analysis of Variance; Animals; Arrhythmias, Cardiac; Catecholamines; Digoxin; Disease Mod | 1995 |
Effect of levamisole hydrochloride on the guinea-pig atrium.
Topics: Animals; Arrhythmias, Cardiac; Atropine; Disease Models, Animal; Drug Antagonism; Drug Evaluation, P | 1993 |
Experimental vasoprotection by calcium antagonists against calcium-mediated arteriosclerotic alterations.
Topics: Adult; Aged; Aged, 80 and over; Animals; Arteriosclerosis; Calcium; Calcium Channel Blockers; Cells, | 1994 |
Hemodynamic effects of 3,4-diaminopyridine in a swine model of verapamil toxicity.
Topics: 4-Aminopyridine; Amifampridine; Animals; Disease Models, Animal; Dose-Response Relationship, Drug; F | 1994 |
Insulin is a superior antidote for cardiovascular toxicity induced by verapamil in the anesthetized canine.
Topics: Anesthesia; Animals; Antidotes; Blood Glucose; Cardiovascular Diseases; Disease Models, Animal; Dogs | 1993 |
Effects of two Ca2+ modulators in normal and albumin-sensitized guinea-pig trachea.
Topics: Acetylcholine; Albumins; Animals; Asthma; Calcium; Disease Models, Animal; Guinea Pigs; Immunization | 1993 |
Verapamil regulation of a defective SR release channel in the cardiomyopathic Syrian hamster.
Topics: Animals; Calcium; Calcium Channels; Cardiomyopathy, Dilated; Cardiotonic Agents; Cricetinae; Disease | 1993 |
Verapamil induced reduction of the myocardial beta-adrenoceptor density in BIO 14.6 cardiomyopathic Syrian hamsters.
Topics: Animals; Binding, Competitive; Calcium Channels; Cardiomyopathies; Cricetinae; Disease Models, Anima | 1993 |
Reversal of Plasmodium falciparum resistance to chloroquine in Panamanian Aotus monkeys.
Topics: Animals; Aotus trivirgatus; Calcium Channel Blockers; Chloroquine; Chlorpromazine; Cyproheptadine; D | 1993 |
Verapamil reduces the size of reperfused ischemically injured myocardium in hypertrophied rat hearts as assessed by magnetic resonance imaging.
Topics: Animals; Aorta, Abdominal; Calcium Channel Blockers; Coloring Agents; Contrast Media; Disease Models | 1996 |
Failure of calcium channel blockade to reduce platelet-mediated cyclic flow variations in dogs with coronary stenosis and endothelial injury.
Topics: Animals; Aspirin; Calcium Channel Blockers; Coronary Circulation; Coronary Disease; Diltiazem; Disea | 1995 |
[Effect of chronic inhibition of nitric oxide synthesis on vascular structure: remodeling or growth?].
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Arginine; Basilar Artery | 1995 |
Pharmacologic characterization of wool dust extract in isolated guinea pig trachea.
Topics: Air Pollutants, Occupational; Animals; Atropine; Bronchoconstriction; Calcium Channel Blockers; Cycl | 1995 |
Compromised microcirculation in acute murine Trypanosoma cruzi infection.
Topics: Acute Disease; Animals; Blood Flow Velocity; Chagas Disease; Dilatation, Pathologic; Disease Models, | 1996 |
Reversal of acute theophylline toxicity by calcium channel blockers in dogs and rats.
Topics: Animals; Arrhythmias, Cardiac; Blood Pressure; Bronchodilator Agents; Calcium; Calcium Channel Block | 1996 |
Pharmacologically induced heart failure for the evaluation of circulatory assistance.
Topics: Anesthetics, Inhalation; Animals; Blood Pressure; Calcium Channel Blockers; Cardiac Output; Cattle; | 1996 |
Effects of verapamil and diltiazem on the ventricular rate during simulated atrial flutter in isolated guinea pig hearts.
Topics: Animals; Atrial Flutter; Calcium Channel Blockers; Diltiazem; Disease Models, Animal; Electrocardiog | 1996 |
Differential effect of selected antiarrhythmic drugs on coronary artery ligation-induced ventricular arrhythmias on the right or left sides.
Topics: Animals; Anti-Arrhythmia Agents; Coronary Disease; Disease Models, Animal; Dogs; Female; Ligation; M | 1995 |
The effects of subconjunctival verapamil on filtering blebs in rabbits.
Topics: Animals; Calcium Channel Blockers; Cell Division; Conjunctiva; Disease Models, Animal; DNA Replicati | 1996 |
Protective effect of verapamil on renal tissue during shockwave application in rabbit model.
Topics: Animals; Calcium Channel Blockers; Disease Models, Animal; Drug Evaluation, Preclinical; Kidney Dise | 1996 |
Cardiac dysrhythmias in severe verapamil overdose: characterization with a canine model.
Topics: Animals; Calcium Channel Blockers; Disease Models, Animal; Dogs; Drug Overdose; Electrocardiography; | 1996 |
The potential synergistic effect of calcium channel blockers and alpha-tocopherol on gastric mucosal injury induced by ischaemia-reperfusion.
Topics: Administration, Oral; Animals; Calcium Channel Blockers; Diltiazem; Disease Models, Animal; Dose-Res | 1996 |
Quinine-induced hearing loss in the guinea pig is not affected by the Ca2+ channel antagonist verapamil.
Topics: Animals; Auditory Threshold; Calcium Channel Blockers; Death, Sudden; Disease Models, Animal; Drug I | 1997 |
The prophylactic effects of superoxide dismutase, catalase, desferrioxamine, verapamil and disulfiram in experimental colitis.
Topics: Acetic Acid; Animals; Calcium Channel Blockers; Catalase; Colitis; Colonic Diseases; Deferoxamine; D | 1997 |
Effects of enalapril, losartan, and verapamil on blood pressure and glucose metabolism in the Cohen-Rosenthal diabetic hypertensive rat.
Topics: Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Biphenyl Compounds; Blood Glucose | 1997 |
Neuroprotective effect of chronic verapamil treatment on cognitive and noncognitive deficits in an experimental Alzheimer's disease in rats.
Topics: Aggression; Alzheimer Disease; Animals; Avoidance Learning; Calcium Channel Blockers; Cognition Diso | 1997 |
Catalepsy induced by calcium channel blockers in mice.
Topics: Amlodipine; Animals; Binding, Competitive; Calcium Channel Blockers; Catalepsy; Dihydropyridines; Di | 1998 |
The effects of verapamil and nimodipine on bupivacaine-induced cardiotoxicity in rats: an in vivo and in vitro study.
Topics: Anesthetics, Local; Animals; Arrhythmias, Cardiac; Blood Pressure; Bupivacaine; Calcium Channel Bloc | 1998 |
Interactions of captopril and verapamil on glucose tolerance and insulin action in an animal model of insulin resistance.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Glucose; Calcium Channel Blockers; Captopri | 1998 |
Severe combined immunodeficiency (SCID) mouse modeling of P-glycoprotein chemosensitization in multidrug-resistant human myeloma xenografts.
Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Calcium Cha | 1995 |
Class differences in the effects of calcium channel blockers in the rat remnant kidney model.
Topics: Animals; Blood Pressure; Calcium Channel Blockers; Diltiazem; Disease Models, Animal; Drinking; Felo | 1999 |
Effects of 17beta-estradiol on tachycardia-induced changes of atrial refractoriness and cisapride-induced ventricular arrhythmia.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Cisapride; Disease Models, Animal; Dogs; Dose-Re | 1999 |
Limitation of shockwave-induced enhanced crystal deposition in traumatized tissue by verapamil in rabbit model.
Topics: Animals; Calcium Channel Blockers; Disease Models, Animal; Kidney; Kidney Calculi; Lithotripsy; Pros | 1999 |
[Comparison of effects of verapamil and those of nicardipine on myocardial ischemia and reperfusion injury: a study in an in situ rabbit model].
Topics: Animals; Anti-Arrhythmia Agents; Calcium Channel Blockers; Disease Models, Animal; Myocardial Ischem | 1999 |
Negative chronotropic and inotropic effects of class I antiarrhythmic drugs assessed in isolated canine blood-perfused sinoatrial node and papillary muscle preparations.
Topics: Animals; Anti-Arrhythmia Agents; Calcium Channel Blockers; Disease Models, Animal; Dogs; Dose-Respon | 1999 |
Tumor necrosis factor-induced lethal hepatitis: pharmacological intervention with verapamil, tannic acid, picotamide and K76COOH.
Topics: Alanine Transaminase; Animals; Apoptosis; Astringents; Chemical and Drug Induced Liver Injury; Compl | 2000 |
Reversal activity of the naturally occurring chemosensitizer malagashanine in Plasmodium malaria.
Topics: Alkaloids; Animals; Antimalarials; Chloroquine; Disease Models, Animal; Drug Interactions; Drug Resi | 2000 |
Effect of antihypertensive drugs on the myocardial microvessels in rats with nitric oxide blockade.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Capillaries; Coronary Circulation; Coronary Vessel | 2000 |
Calcium and digoxin vs. calcium alone for severe verapamil toxicity.
Topics: Animals; Calcium; Calcium Channel Blockers; Chi-Square Distribution; Digoxin; Disease Models, Animal | 2000 |
Hypertonic sodium bicarbonate is effective in the acute management of verapamil toxicity in a swine model.
Topics: Animals; Blood Pressure Determination; Disease Models, Animal; Drug-Related Side Effects and Adverse | 2000 |
Sarcoglycan, the heart, and skeletal muscles: new treatment, old drug?
Topics: Animals; Cardiomyopathies; Cytoskeletal Proteins; Disease Models, Animal; Dystroglycans; Dystrophin; | 2001 |
Prevention of cardiomyopathy in mouse models lacking the smooth muscle sarcoglycan-sarcospan complex.
Topics: Age Factors; Animals; Cardiomyopathies; Carrier Proteins; Coronary Circulation; Cytoskeletal Protein | 2001 |
Mechanisms of the increased pressor response to vasopressors in the mesenteric bed of nitric oxide-deficient hypertensive rats.
Topics: Acetylcholine; Animals; Antihypertensive Agents; Arteries; Blood Pressure; Disease Models, Animal; D | 2001 |
Profibrillatory effects of verapamil but not of digoxin in the goat model of atrial fibrillation.
Topics: Acute Disease; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Pacing, Artificial; Chr | 2000 |
Lead-cadmium interaction effect on the responsiveness of rat mesenteric vessels to norepinephrine and angiotensin II.
Topics: Analysis of Variance; Angiotensin II; Animals; Cadmium Poisoning; Calcium; Dinoprostone; Disease Mod | 2001 |
Inhibitory effects of verapamil and nitroglycerin on contraction and cytosolic Ca2+ levels in cerebrovascular smooth muscle during chronic cerebral vasospasm.
Topics: Animals; Calcium Channel Blockers; Calcium Channels; Chronic Disease; Cytosol; Disease Models, Anima | 2001 |
Calcium channel antagonist verapamil inhibits neointimal formation and enhances apoptosis in a vascular graft model.
Topics: Analysis of Variance; Animals; Apoptosis; Calcium Channel Blockers; Carotid Artery, Common; Disease | 2001 |
Short-term histopathologic effects of different intracavernosal agents on corpus cavernosum and antifibrotic activity of intracavernosal verapamil: an experimental study.
Topics: Alprostadil; Animals; Calcium Channel Blockers; Chemical and Drug Induced Liver Injury; Disease Mode | 2001 |
Cardioprotective effects of verapamil on myocardial structure and function in a murine model of chronic Trypanosoma cruzi infection (Brazil Strain): an echocardiographic study.
Topics: Animals; Calcium Channel Blockers; Cardiotonic Agents; Chagas Disease; Collagen; Disease Models, Ani | 2002 |
Effects of a calcium channel blocker on electrical activity in myofascial trigger spots of rabbits.
Topics: Action Potentials; Animals; Calcium Channel Blockers; Disease Models, Animal; Electromyography; Hind | 2002 |
Mibefradil improves beta-adrenergic responsiveness and intracellular Ca(2+) handling in hypertrophied rat myocardium.
Topics: Adrenergic beta-Agonists; Aequorin; Animals; Calcium; Calcium Channel Blockers; Calcium Channels, T- | 2002 |
[Proceedings: Prevention of myocardial degeneration in a disease model of hereditary cardiomyopathy].
Topics: Animals; Calcium; Cardiomegaly; Cardiomyopathies; Cricetinae; Disease Models, Animal; Heart; Myocard | 1975 |
Reduction in infarct size following experimental coronary occlusion by administration of verapamil.
Topics: Animals; Blood Pressure; Cardiac Output; Coronary Circulation; Coronary Disease; Disease Models, Ani | 1975 |
Effect of drugs on conduction delay and incidence of ventricular arrhythmias induced by acute coronary occlusion in dogs.
Topics: Animals; Aprindine; Arrhythmias, Cardiac; Coronary Disease; Disease Models, Animal; Dogs; Heart Cond | 1977 |
Effects of verapamil on regional myocardial blood flow and ST segment. Role of the induced bradycardia.
Topics: Animals; Blood Pressure; Bradycardia; Coronary Circulation; Coronary Disease; Disease Models, Animal | 1976 |
Epicardial controlled-release verapamil prevents ventricular tachycardia episodes induced by acute ischemia in a canine model.
Topics: Animals; Coronary Disease; Delayed-Action Preparations; Disease Models, Animal; Dogs; Dose-Response | 1992 |
[Prostacyclin-thromboxane imbalance after adrenergic damage of the heart and aorta and its correction with calcium antagonist finoptin and the adaptation to high-altitude climate].
Topics: Adaptation, Physiological; Altitude; Animals; Aorta, Abdominal; Disease Models, Animal; Epinephrine; | 1992 |
Effects of intravesically administered verapamil HC1 (calcium entry blocker) on the bladder function in unanesthetized rats.
Topics: Administration, Intravesical; Animals; Calcium Channel Blockers; Disease Models, Animal; Male; Rats; | 1992 |
Postischaemic hypercontraction is enhanced in ischaemically injured canine myocardium.
Topics: Animals; Calcium; Coronary Disease; Disease Models, Animal; Dogs; Myocardial Contraction; Myocardial | 1992 |
Detecting fabrication of data in a multicenter collaborative animal study.
Topics: Animals; Data Interpretation, Statistical; Disease Models, Animal; Dogs; Ibuprofen; Multicenter Stud | 1991 |
The proliferative response to vascular injury is suppressed by angiotensin-converting enzyme inhibition.
Topics: Angioplasty, Balloon, Coronary; Angiotensin-Converting Enzyme Inhibitors; Animals; Blotting, Norther | 1990 |
Effects of levemopamil on neurologic and histologic outcome after cardiac arrest in cats.
Topics: Animals; Blood Gas Analysis; Brain Ischemia; Cardiopulmonary Resuscitation; Cats; Disease Models, An | 1992 |
[Effects of verapamil on cyclosporine. A (CsA)-induced nephropathy in ischemic kidney model in rats: changes in systemic hemodynamics and hepatic and renal microsomal cytochrome P-450].
Topics: Animals; Cyclosporine; Cytochrome P-450 Enzyme System; Disease Models, Animal; Enzyme Induction; Hem | 1991 |
[Verapamil and nifedipine limit hemodynamic changes in pulmonary circulation in rats with hypoxia].
Topics: Animals; Antihypertensive Agents; Blood Pressure; Depression, Chemical; Disease Models, Animal; Hype | 1991 |
[Effects of verapamil and nitroglycerin on experimental occlusion- reperfusion-induced myocardial infarction in rabbits].
Topics: Animals; Coronary Vessels; Disease Models, Animal; Drug Evaluation, Preclinical; Ligation; Male; Myo | 1991 |
Effect of hyperkalemia on experimental myocardial depression by verapamil.
Topics: Acute Disease; Animals; Bradycardia; Calcium; Depression, Chemical; Disease Models, Animal; Dogs; Dr | 1991 |
Dose-related effects of isoflurane associated with low plasma concentrations of verapamil on global and regional function in normal and compromised canine myocardium.
Topics: Animals; Blood Pressure; Coronary Circulation; Coronary Disease; Disease Models, Animal; Dogs; Dose- | 1991 |
Effects of calcium and calcium antagonists against deprivation of glucose and oxygen in guinea pig hippocampal slices.
Topics: Action Potentials; Animals; Brain Ischemia; Calcium; Calcium Channel Blockers; Disease Models, Anima | 1990 |
Calcium-entry blockers during porcine cardiopulmonary resuscitation.
Topics: Animals; Blood Pressure; Diltiazem; Disease Models, Animal; Heart Arrest; Hydrogen-Ion Concentration | 1990 |
Calcium antagonists and myocardial protection: a comparative study of the functional, metabolic and electrical consequences of verapamil and nifedipine as additives to the St. Thomas' cardioplegic solution.
Topics: Animals; Arrhythmias, Cardiac; Calcium; Cardiac Output; Cardiopulmonary Bypass; Disease Models, Anim | 1985 |
Effect of verapamil on the development of chronic experimental Chagas' disease.
Topics: Adenylyl Cyclases; Animals; Chagas Cardiomyopathy; Chagas Disease; Chronic Disease; Disease Models, | 1989 |
[Treatment of cardiomyopathy using Ca blockers].
Topics: Animals; Calcium Channel Blockers; Cardiomyopathy, Dilated; Cardiomyopathy, Hypertrophic; Cricetinae | 1989 |
Effect of antisecretory drugs on experimentally induced weanling diarrhoea in piglets.
Topics: Animals; Animals, Newborn; Chlorpromazine; Clonidine; Diarrhea; Disease Models, Animal; Escherichia | 1989 |
Long-term neurological assessment of the post-resuscitative effects of flunarizine, verapamil and nimodipine in a new model of global complete ischaemia.
Topics: Anesthesia; Animals; Behavior, Animal; Disease Models, Animal; Electroencephalography; Electromyogra | 1989 |
Transvenous perfusion of the brain with verapamil during focal cerebral ischemia in rats.
Topics: Acute Disease; Animals; Autoradiography; Blood Gas Analysis; Blood Pressure; Brain Ischemia; Cerebra | 1989 |
Calcium antagonist receptors in cardiomyopathic hamster: selective increases in heart, muscle, brain.
Topics: Animals; Brain; Brain Chemistry; Calcium; Calcium Channels; Cardiomyopathy, Hypertrophic; Cricetinae | 1986 |
Platelet-activating factor-induced ischemic bowel necrosis. An investigation of secondary mediators in its pathogenesis.
Topics: Alprostadil; Animals; Blood Pressure; Catechols; Chromones; Diethylcarbamazine; Disease Models, Anim | 1986 |
Comparison of verapamil and nifedipine in thrombosis models.
Topics: Animals; Arachidonic Acid; Arachidonic Acids; Collagen; Disease Models, Animal; Epinephrine; Male; N | 1986 |
Combination of ribose with calcium antagonist and beta-blocker treatment in closed-chest rats.
Topics: Adenine Nucleotides; Animals; Cardiac Output; Disease Models, Animal; Dose-Response Relationship, Dr | 1987 |
[Mechanisms of the anomalous activity of the Purkinje fibers in the late stage of experimental myocardial infarct in dogs].
Topics: Action Potentials; Animals; Calcium; Disease Models, Animal; Dogs; Electrocardiography; Heart Conduc | 1988 |
Quantification of arrhythmias using scoring systems: an examination of seven scores in an in vivo model of regional myocardial ischaemia.
Topics: Animals; Arrhythmias, Cardiac; Coronary Disease; Disease Models, Animal; Dose-Response Relationship, | 1988 |
Effect of verapamil on posttransplant acute renal failure in the canine kidney.
Topics: Acute Kidney Injury; Animals; Disease Models, Animal; Dogs; Female; Kidney; Kidney Transplantation; | 1988 |
[Approaches to the creation of a model of cerebral thrombocytic microembolism and to research on the effects of drugs].
Topics: Acid-Base Equilibrium; Animals; Blood Pressure; Cats; Collagen; Disease Models, Animal; Drug Evaluat | 1987 |
Effect of the calcium entry blocker verapamil on renal ischemia.
Topics: Acute Kidney Injury; Animals; Creatinine; Disease Models, Animal; Ischemia; Kidney; Sheep; Verapamil | 1988 |
Remnant kidney hypermetabolism and progression of chronic renal failure.
Topics: Animals; Disease Models, Animal; Kidney; Kidney Failure, Chronic; Male; Oxygen Consumption; Perfusio | 1988 |
Modulation of ischemic-induced damage to cerebral adenylate cyclase in gerbils by calcium channel blockers.
Topics: Adenylyl Cyclases; Animals; Calcium Channel Blockers; Disease Models, Animal; Female; Flunarizine; G | 1986 |
Brief periods of myocardial ischemia followed by reperfusion: a model in the dog of sudden cardiac death in humans.
Topics: Animals; Collateral Circulation; Coronary Circulation; Coronary Disease; Death, Sudden; Disease Mode | 1987 |
Limitation of infarct size for 24 hours by combined treatment with allopurinol plus verapamil during acute myocardial infarction in the dog.
Topics: Allopurinol; Animals; Coronary Circulation; Disease Models, Animal; Dogs; Drug Evaluation, Preclinic | 1987 |
The antithrombogenic in vivo effects of calcium channel blockers in experimental thrombosis in mice.
Topics: Animals; Calcium Channel Blockers; Collagen; Dihydropyridines; Diltiazem; Disease Models, Animal; Do | 1987 |
[Effect of dibunol and isoptin on the creatine kinase and myoglobin content of the blood serum in dogs undergoing postischemic coronary reperfusion].
Topics: Animals; Antioxidants; Butylated Hydroxytoluene; Calcium Channel Blockers; Coronary Disease; Creatin | 1987 |
Effects of antiarrhythmic agents on isoproterenol-induced ventricular fibrillation in heavy rats: a possible model of sudden cardiac death.
Topics: Animals; Anti-Arrhythmia Agents; Body Weight; Bretylium Tosylate; Death, Sudden; Disease Models, Ani | 1986 |
Pharmacokinetics and dynamics of (+/-)-verapamil in lean and obese Zucker rats.
Topics: Animals; Blood Pressure; Blood Proteins; Body Weight; Disease Models, Animal; Female; Kinetics; Obes | 1986 |
Animal models for protecting ischemic myocardium: results of the NHLBI Cooperative Study. Comparison of unconscious and conscious dog models.
Topics: Anesthesia; Animal Testing Alternatives; Animals; Arterial Occlusive Diseases; Coronary Circulation; | 1985 |
Verapamil preserves adenine nucleotide pool in cardiomyopathic Syrian hamster.
Topics: Adenine Nucleotides; Animals; Body Weight; Collagen; Cricetinae; Disease Models, Animal; Heart Failu | 1986 |
Evaluation of a rat model for assessing interventions to salvage ischaemic myocardium: effects of ibuprofen and verapamil.
Topics: Animals; Body Weight; Creatine Kinase; Disease Models, Animal; Ibuprofen; Male; Myocardial Infarctio | 1985 |
Failure of a slow channel calcium antagonist, verapamil, to retard atherosclerosis in the Watanabe heritable hyperlipidemic rabbit: an animal model of familial hypercholesterolemia.
Topics: Animals; Arteriosclerosis; Calcium Channel Blockers; Disease Models, Animal; Female; Hyperlipidemias | 1985 |
[An experimental animal model study on the effect of antiarrhythmic drugs for the prophylaxis of supraventricular tachycardia].
Topics: Animals; Anti-Arrhythmia Agents; Disease Models, Animal; Dogs; Propranolol; Tachycardia; Verapamil | 1985 |
Nicardipine in models of myocardial infarction.
Topics: Animals; Calcium Channel Blockers; Disease Models, Animal; Dogs; Electrocardiography; Heart Conducti | 1985 |